

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number
WO 2004/055009 A1

(51) International Patent Classification⁷: **C07D 403/12**,
403/14, 401/12, 401/14, 413/14, A61K 31/497, 31/496,
31/5377, A61P 25/00, 3/10, 5/48, 15/18, 17/14

SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/SE2003/001957

(22) International Filing Date:
15 December 2003 (15.12.2003)

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Declaration under Rule 4.17:

(26) Publication Language: English

(30) Priority Data:
0203753-9 17 December 2002 (17.12.2002) SE

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,
IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD,
SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,
LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG)

(71) Applicant (*for all designated States except US*): AS-
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BERG, Ste-
fan [SE/SE]; AstraZeneca R & D Södertälje, S-151
85 Södertälje (SE). HELLBERG, Sven [SE/SE]; As-
traZeneca R & D Södertälje, S-151 85 Södertälje (SE).

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; As-
traZeneca AB, S-151 85 Södertälje (SE).


Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NOBEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3



(i)

(57) Abstract: The present invention relates to new compounds of
formula (I) wherein Z is N; Y is CONR⁵, NR⁵CO, SO₂NR⁵, NR⁵SO₂,
CH₂NR⁵, NR⁵, NR⁵CONR⁵, CH₂CO, CO, O or CH₂O; X is CH or N;
P is phenyl or a 5 or 6 membered heteroaromatic ring containing one
or more heteroatoms selected from N, O or S and said phenyl ring or 5
or 6 membered heteroaromatic ring may optionally be fused with a 5
or 6 membered saturated, partially saturated or unsaturated ring con-
taining one or more atoms selected from C, N, O or S; Q is C₁₋₆alkyl,
C₂₋₆alkenyl or C₂₋₆alkynyl, a process for their preparation and new in-
termediates used therein, pharmaceutical formulations containing said

therapeutically active compounds and to the use of said active compounds in therapy, such as provide compounds having a selective
inhibiting effect at GSK3.

Novel compounds having selective inhibiting effect at GSK3.

FIELD OF THE INVENTION

5

The present invention relates to new compounds of formula I, as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, to pharmaceutical formulations containing said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of compounds of formula I and to new intermediates used in the preparation thereof.

10

BACKGROUND OF THE INVENTION

Glycogen synthase kinase 3 (GSK3) is a serine / threonine protein kinase composed of two isoforms (α and β), which are encoded by distinct genes but are highly homologous within the catalytic domain. GSK3 is highly expressed in the central and peripheral nervous system. GSK3 phosphorylates several substrates including tau, β -catenin, glycogen synthase, pyruvate dehydrogenase and elongation initiation factor 2b (eIF2b). Insulin and growth factors activate protein kinase B, which phosphorylates GSK3 on serine 9 residue and inactivates it.

20

Alzheimer's Disease (AD) dementias, and tauopathies.

AD is characterized by cognitive decline, cholinergic dysfunction and neuronal death, neurofibrillary tangles and senile plaques consisting of amyloid- β deposits. The sequence of these events in AD is unclear, but is believed to be related. Glycogen synthase kinase 3 β (GSK3 β) or Tau (τ) phosphorylating kinase selectively phosphorylates the microtubule associated protein τ in neurons at sites that are hyperphosphorylated in AD brains. Hyperphosphorylated protein τ has lower affinity for microtubules and accumulates as paired helical filaments, which are the main components that constitute neurofibrillary tangles and neuropil threads in AD brains. This results in depolymerization of microtubules, which leads to dying back of axons and neuritic dystrophy. Neurofibrillary

30

tangles are consistently found in diseases such as AD, amyotrophic lateral sclerosis, parkinsonism-dementia of Gaum, corticobasal degeneration, dementia pugilistica and head trauma, Down's syndrome, postencephalatic parkinsonism, progressive supranuclear palsy, Niemann-Pick's Disease and Pick's Disease. Addition of amyloid- β to primary
5 hippocampal cultures results in hyperphosphorylation of τ and a paired helical filaments-like state via induction of GSK3 β activity, followed by disruption of axonal transport and neuronal death (Imahori and Uchida., J. Biochem 121:179-188, 1997). GSK3 β preferentially labels neurofibrillary tangles and has been shown to be active in pre-tangle neurons in AD brains. GSK3 protein levels are also increased by 50% in brain tissue from
10 AD patients. Furthermore, GSK3 β phosphorylates pyruvate dehydrogenase, a key enzyme in the glycolytic pathway and prevents the conversion of pyruvate to acetyl-Co-A (Hoshi et al., PNAS 93:2719-2723, 1996). Acetyl-Co-A is critical for the synthesis of acetylcholine, a neurotransmitter with cognitive functions. Thus, GSK3 β inhibition may have beneficial effects in progression as well as the cognitive deficits associated with Alzheimer's disease
15 and other above-referred to diseases.

Chronic and Acute Neurodegenerative Diseases.

Growth factor mediated activation of the PI3K /Akt pathway has been shown to play a key role in neuronal survival. The activation of this pathway results in GSK3 β inhibition.
20 Recent studies (Bhat et. al., PNAS 97:11074-11079 (2000)) indicate that GSK3 β activity is increased in cellular and animal models of neurodegeneration such as cerebral ischemia or after growth factor deprivation. For example, the active site phosphorylation was increased in neurons vulnerable to apoptosis, a type of cell death commonly thought to occur in chronic and acute degenerative diseases such as Alzheimer's Disease, Parkinson's Disease,
25 amyotrophic lateral sclerosis, Huntington's Disease and HIV dementia, ischemic stroke and head trauma. Lithium was neuroprotective in inhibiting apoptosis in cells and in the brain at doses that resulted in the inhibition of GSK3 β . Thus GSK3 β inhibitors could be useful in attenuating the course of neurodegenerative diseases.

Bipolar Disorders (BD)

Bipolar Disorders are characterised by manic episodes and depressive episodes. Lithium has been used to treat BD based on its mood stabilising effects. The disadvantage of lithium is the narrow therapeutic window and the danger of overdosing that can lead to lithium intoxication. The recent discovery that lithium inhibits GSK3 at therapeutic concentrations has raised the possibility that this enzyme represents a key target of lithium's action in the brain (Stambolic et al., Curr. Biol. 6:1664-1668, 1996; Klein and Melton; PNAS 93:8455-8459, 1996). Inhibition of GSK3 β may therefore be of therapeutic relevance in the treatment of BD as well as in AD patients that have affective disorders.

Schizophrenia

GSK3 is involved in signal transduction cascades of multiple cellular processes, particularly during neural development. Kozlovsky et al (Am J Psychiatry 2000 May;157(5):831-3) found that GSK3 β levels were 41% lower in the schizophrenic patients than in comparison subjects. This study indicates that schizophrenia involves neurodevelopmental pathology and that abnormal GSK3 regulation could play a role in schizophrenia. Furthermore, reduced β -catenin levels have been reported in patients exhibiting schizophrenia (Cotter et al., Neuroreport 9:1379-1383 (1998)).

Diabetes

Insulin stimulates glycogen synthesis in skeletal muscles via the dephosphorylation and thus activation of glycogen synthase. Under resting conditions, GSK3 phosphorylates and inactivates glycogen synthase via dephosphorylation. GSK3 is also over-expressed in muscles from Type II diabetic patients (Nikoulina et al., Diabetes 2000 Feb;49(2):263-71). Inhibition of GSK3 increases the activity of glycogen synthase thereby decreasing glucose levels by its conversion to glycogen. GSK3 inhibition may therefore be of therapeutic relevance in the treatment of Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders.

Hair Loss


GSK3 phosphorylates and degrades β -catenin. β -catenin is an effector of the pathway for keratin synthesis. β -catenin stabilisation may lead to increase hair development. Mice expressing a stabilised β -catenin by mutation of sites phosphorylated by GSK3 undergo a process resembling de novo hair morphogenesis (Gat et al., Cell 1998 Nov 25;95 (5):605-14)). The new follicles formed sebaceous glands and dermal papilla, normally established only in embryogenesis. Thus GSK3 inhibition may offer treatment for baldness.

Oral contraceptives

Vijayaraghavan et al. (Biol Reprod 2000 Jun; 62 (6):1647-54) reported that GSK3 is high in motile versus immotile sperm. Immunocytochemistry revealed that GSK3 is present in the flagellum and the anterior portion of the sperm head. These data suggest that GSK3 could be a key element underlying motility initiation in the epididymis and regulation of mature sperm function. Inhibitors of GSK3 could be useful as contraceptives for males.

DISCLOSURE OF THE INVENTION

The object of the present invention is to provide compounds having a selective inhibiting effect at GSK3 as well as having a good bioavailability. Accordingly, the present invention provides a compound of formula I:



wherein:

Z is N;

Y is CONR^5 , NR^5CO , SO_2NR^5 , NR^5SO_2 , CH_2NR^5 , NR^5CONR^5 , CH_2CO , CO or CH_2O ;

X is CH or N;

P is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected from N, O or S and said phenyl ring or 5 or 6 membered heteroaromatic ring may optionally be fused with a 5 or 6 membered saturated, partially saturated or unsaturated ring containing atoms independently selected from C, N, O or S;

5 Q is C₁₋₆alkyl, C₂₋₆alkenyl or C₂₋₆alkynyl;

R is CHO, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C₀₋₆alkyl(SO₂)NR¹R², OC₀₋₆alkyl(SO₂)NR¹R², OC₁₋₆alkyl(SO)NR¹R², C₁₋₆alkyl(SO)NR¹R², C₀₋₆alkylNR¹(SO)R², OC₁₋₆alkylNR¹(SO)R², C₀₋₆alkylNR¹(SO₂)NR¹R², OC₁₋₆alkylNR¹(SO₂)R², C₀₋₆alkyl(SO₂)C₁₋₆alkylNR¹R², OC₀₋₆alkyl(SO₂)C₁₋₆alkylNR¹R², C₀₋₆alkyl(SO)C₁₋₆alkylNR¹R², OC₁₋₆alkyl(SO)C₁₋₆alkylNR¹R², C₀₋₆alkylSC₁₋₆alkylNR¹R², OC₁₋₆alkylSC₁₋₆alkylNR¹R², OC₁₋₆alkylOC₁₋₆alkyl, C₁₋₆alkylOC₁₋₆alkylNR¹R², OC₁₋₆alkylOC₁₋₆alkylNR¹R², C₀₋₆alkylCONR¹⁰R¹¹, OC₀₋₆alkylCONR¹R², OC₁₋₆alkylNR¹R², C₀₋₆alkylNR¹⁰(CO)R¹¹, OC₁₋₆alkylNR¹(CO)R², C₀₋₆alkylNR¹¹(CO)R¹⁰, C₀₋₆alkylCOR¹¹, OC₁₋₆alkylCOR¹, C₀₋₆alkylNR¹⁰R¹¹, C₀₋₆alkylO(CO)R¹¹, OC₁₋₆alkylO(CO)R¹, C₀₋₆alkylC(NR¹⁰)NR¹⁰R¹¹, C₀₋₆alkylC(NR¹¹)N(R¹⁰)₂, OC₀₋₆alkylC(NR¹)NR¹R², C₀₋₆alkylNR¹⁰(CO)OR¹¹, OC₁₋₆alkylNR¹(CO)OR², C₀₋₆alkylNR¹¹(CO)OR¹⁰, OC₁₋₆alkylCN, NR¹OR², C₀₋₆alkyl(CO)OR⁸, OC₁₋₆alkyl(CO)OR¹, NR¹(CO)NR¹R², NR¹(CO)(CO)R², NR¹(CO)(CO)NR¹R², OR¹² or SO₃R¹;

R¹ and R² are independently selected from hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,

20 C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylheterocycloalkyl, C₁₋₆alkylNR⁶R⁷, C₀₋₆alkylaryl and C₀₋₆alkylheteroaryl, wherein any C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylheterocycloalkyl, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl may be substituted by one or more A;

R¹ and R² may together form a substituted 5 or 6 membered heterocyclic ring containing
25 one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A;

R³ is independently selected from halogen, nitro, CHO, C₀₋₆alkylCN, OC₁₋₆alkylCN, C₀₋₆alkylOR⁶, OC₁₋₆alkylOR⁶, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C₀₋₆alkylNR⁶R⁷, OC₁₋₆alkylNR⁶R⁷, OC₁₋₆alkylOC₁₋₆alkylNR⁶R⁷, NR⁶OR⁷, C₀₋₆alkylCO₂R⁶, OC₁₋₆alkylCO₂R⁶, C₀₋₆alkylCONR⁶R⁷, OC₁₋₆alkylCONR⁶R⁷, OC₁₋₆alkylNR⁶(CO)R⁷, C₀₋₆alkylNR⁶(CO)R⁷, O(CO)NR⁶R⁷, NR⁶(CO)OR⁷, NR⁶(CO)NR⁶R⁷, O(CO)OR⁶, O(CO)R⁶, C₀₋₆alkylCOR⁶,

30

- $\text{OC}_{1-6}\text{alkylCOR}^6$, $\text{NR}^6(\text{CO})(\text{CO})\text{R}^6$, $\text{NR}^6(\text{CO})(\text{CO})\text{NR}^6\text{R}^7$, SR^6 , $\text{C}_{0-6}\text{alkyl}(\text{SO}_2)\text{NR}^6\text{R}^7$,
 $\text{OC}_{1-6}\text{alkylNR}^6(\text{SO}_2)\text{R}^7$, $\text{OC}_{0-6}\text{alkyl}(\text{SO}_2)\text{NR}^6\text{R}^7$, $\text{C}_{0-6}\text{alkyl}(\text{SO})\text{NR}^6\text{R}^7$,
 $\text{OC}_{1-6}\text{alkyl}(\text{SO})\text{NR}^6\text{R}^7$, SO_3R^6 , $\text{C}_{0-6}\text{alkylNR}^6(\text{SO}_2)\text{NR}^6\text{R}^7$, $\text{C}_{0-6}\text{alkylNR}^6(\text{SO})\text{R}^7$,
 $\text{OC}_{1-6}\text{alkylNR}^6(\text{SO})\text{R}^7$, $\text{OC}_{0-6}\text{alkylSO}_2\text{R}^6$, $\text{C}_{0-6}\text{alkylSO}_2\text{R}^6$, $\text{C}_{0-6}\text{alkylSOR}^6$, $\text{C}_{1-6}\text{alkyl}$,
 5 $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, $\text{C}_{0-6}\text{alkylC}_{3-6}\text{cycloalkyl}$, $\text{C}_{0-6}\text{alkylaryl}$ and $\text{C}_{0-6}\text{alkylheteroaryl}$,
 wherein any $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, $\text{C}_{0-6}\text{alkylC}_{3-6}\text{cycloalkyl}$, $\text{C}_{0-6}\text{alkylaryl}$ and
 $\text{C}_{0-6}\text{alkylheteroaryl}$ may be optionally substituted by one or more A;
 R^4 is independently selected from halogen, nitro, CHO, CN, $\text{OC}_{1-6}\text{alkylCN}$, OR^6 ,
 $\text{OC}_{1-6}\text{alkylOR}^6$, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy,
 10 difluoromethoxy, trifluoromethoxy, NR^6R^7 , $\text{OC}_{1-6}\text{alkylNR}^6\text{R}^7$, NR^6OR^7 , CO_2R^6 ,
 $\text{OC}_{1-6}\text{alkylCO}_2\text{R}^6$, CONR^6R^7 , $\text{OC}_{1-6}\text{alkylCONR}^6\text{R}^7$, $\text{OC}_{1-6}\text{alkylNR}^6(\text{CO})\text{R}^7$, $\text{NR}^6(\text{CO})\text{R}^7$,
 $\text{O}(\text{CO})\text{NR}^6\text{R}^7$, $\text{NR}^6(\text{CO})\text{OR}^7$, $\text{NR}^6(\text{CO})\text{NR}^6\text{R}^7$, $\text{O}(\text{CO})\text{OR}^6$, $\text{O}(\text{CO})\text{R}^6$, COR^6 ,
 $\text{OC}_{1-6}\text{alkylCOR}^6$, $\text{NR}^6(\text{CO})(\text{CO})\text{R}^6$, $\text{NR}^6(\text{CO})(\text{CO})\text{NR}^6\text{R}^7$, SR^6 , $(\text{SO}_2)\text{NR}^6\text{R}^7$,
 $\text{OC}_{1-6}\text{alkylNR}^6(\text{SO}_2)\text{R}^7$, $\text{OC}_{0-6}\text{alkyl}(\text{SO}_2)\text{NR}^6\text{R}^7$, $(\text{SO})\text{NR}^6\text{R}^7$, $\text{OC}_{1-6}\text{alkyl}(\text{SO})\text{NR}^6\text{R}^7$,
 15 SO_3R^6 , $\text{NR}^6(\text{SO}_2)\text{NR}^6\text{R}^7$, $\text{NR}^6(\text{SO})\text{R}^7$, $\text{OC}_{1-6}\text{alkylNR}^6(\text{SO})\text{R}^7$, $\text{OC}_{0-6}\text{alkylSO}_2\text{R}^6$, SO_2R^6 ,
 SOR^6 , $\text{C}_{3-6}\text{cycloalkyl}$, phenyl, a 5 or 6 membered heteroaromatic ring containing one or
 more heteroatoms independently selected from N, O, or S, or a 5 or 6 membered
 heterocyclic ring containing one or more heteroatoms independently selected from N, O, or
 S which heterocyclic group may be saturated or unsaturated, and said phenyl ring or 5 or 6
 20 membered heteroaromatic ring or 5 or 6 membered heterocyclic ring may optionally be
 fused with a 5 or 6 membered saturated, partially saturated or unsaturated ring containing
 atoms independently selected from C, N, O or S wherein any $\text{C}_{3-6}\text{cycloalkyl}$, phenyl, 5 or 6
 membered heteroaromatic ring with one or two heteroatoms selected independently from
 N, O, or S or a 5 or 6 membered heterocyclic ring containing one or two heteroatoms
 25 selected independently from N, O, or S; may be optionally be substituted by one or more
 A;
 m is 0, 1, 2, 3 or 4;
 n is 0, 1, 2, 3 or 4;
 R^5 is hydrogen or $\text{C}_{1-6}\text{alkyl}$
 30 R^6 and R^7 are independently selected from hydrogen, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$,
 $\text{C}_{0-6}\text{alkylC}_{3-6}\text{cycloalkyl}$, $\text{C}_{0-6}\text{alkylaryl}$, $\text{C}_{0-6}\text{alkylheteroaryl}$ and $\text{C}_{1-6}\text{alkylNR}^6\text{R}^7$;

- R^6 and R^7 may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A and wherein a CH_2 group may optionally be replaced by a CO group;
- 5 R^8 and R^9 are independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{0-6} alkyl C_{3-6} cycloalkyl, C_{0-6} alkylaryl and C_{0-6} alkylheteroaryl;
 R^8 and R^9 may together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which heterocyclic ring may be optionally substituted by A;
- 10 R^{10} is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{0-6} alkyl C_{3-6} cycloalkyl, C_{0-6} alkylaryl, C_{0-6} alkylheteroaryl or C_{1-6} alkyl NR^8R^9 ;
 R^{11} is C_{1-6} alkyl NR^8R^9 ;
 R^{10} and R^{11} may together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which heterocyclic ring may be optionally substituted by A;
- 15 R^{12} is a 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A; wherein any C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{0-6} alkyl C_{3-6} cycloalkyl, C_{0-6} alkylheterocycloalkyl, C_{0-6} alkylaryl, C_{0-6} alkylheteroaryl defined under R^5 to R^{12} may
- 20 be substituted by one or more A;
A is halogen, nitro, oxo (=O), CHO, CN, OR^6 , C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{0-6} alkyl C_{3-6} cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C_{0-6} alkyl NR^6R^7 , OC_{1-6} alkyl NR^6R^7 , CO_2R^8 , $CONR^6R^7$, $NR^6(CO)R^6$, $O(CO)R^6$, COR^6 , SR^6 , $(SO_2)NR^6R^7$, $(SO)NR^6R^7$, SO_3R^6 , SO_2R^6 or SOR^6 ;
- 25 as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

One aspect of the invention relates to compounds of formula I, wherein wherein Z and X is N; P is phenyl; R is C_{0-6} alkyl $(SO_2)NR^1R^2$; and m is 0.

In one embodiment of this aspect, R^1 and R^2 in $C_{0-6}alkyl(SO_2)NR^1R^2$ together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S.

- 5 In another embodiment of this aspect, there are provided such compounds wherein said heterocyclic ring comprises one or more N heteroatoms and said heterocyclic ring is optionally substituted by A, preferably a $C_{1-6}alkyl$.

- Another aspect of the invention relates to compounds of formula I, wherein Y is $CONR^5$;
10 R^5 is hydrogen; Q is $C_{1-6}alkyl$; R^4 is selected from: phenyl, a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms independently selected from N, O, or S or a 5 or 6 membered heterocyclic ring containing one or two heteroatoms selected independently from N, O, or S which heterocyclic group may be saturated or unsaturated, CN, OR^6 , SO_2R^6 , $NR^6(CO)R^7$, $(SO_2)NR^6R^7$, and $CONR^6R^7$; and n is 1; said phenyl, 5 or 6
15 membered heteroaromatic ring or 5 or 6 membered heterocyclic ring may optionally be substituted by A.

One embodiment of this aspect relates to compounds wherein A is selected from OR^6 , $C_{1-6}alkyl$, oxo (=O) and nitro; and R^6 and/or R^7 are selected from $C_{1-6}alkyl$ and hydrogen.

20

In a further aspect of the invention the following compounds are provided:

3-Amino-N-(2-cyanoethyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;

- 3-Amino-N-(3-amino-3-oxopropyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-
25 carboxamide;

3-Amino-N-(2-nitrobenzyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;

3-Amino-N-(2-methoxybenzyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-
carboxamide;

- 3-Amino-N-(3-morpholin-4-ylpropyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-
30 carboxamide;

3-Amino-*N*-[3-(4-methylpiperazin-1-yl)propyl]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;

as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof,


- 5 3-Amino-*N*-(2-morpholin-4-ylethyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide hydrochloride;
- 3-Amino-*N*-[2-(1*H*-imidazol-4-yl)ethyl]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide hydrochloride;
- 3-Amino-*N*-[3-(1*H*-imidazol-1-yl)propyl]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-
10 carboxamide hydrochloride;
- 3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-(2-thien-2-ylethyl)pyrazine-2-carboxamide hydrochloride;
- 3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-(thien-2-ylmethyl)pyrazine-2-carboxamide hydrochloride;
- 15 3-Amino-*N*-(2-methoxyethyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;
- 3-Amino-*N*-(3-methoxypropyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;
- 3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]pyrazine-2-carboxamide hydrochloride;
- 20 3-Amino-*N*-(cyanomethyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide dihydrochloride;
- 3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[2-(1*H*-pyrrol-1-yl)ethyl]-2-pyrazinecarboxamide hydrochloride;
- 25 3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[2-(methylsulfonyl)ethyl]-2-pyrazinecarboxamide hydrochloride;
- N*-[2-(Acetylamino)ethyl]-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;
- 3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[2-(2-oxo-1-
30 imidazolidinyl)ethyl]-2-pyrazinecarboxamide hydrochloride;
- 3-Amino-*N*-[2-(aminosulfonyl)ethyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;

or as a free base or an alternative pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

Another aspect of the invention is the compounds of formulas XIXa, IV, XXII, which are useful as intermediates in the preparation of compounds of formula I.

5

A compound of formula XIXa



10 wherein

P is phenyl

R¹ and R² are independently selected from hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylheterocycloalkyl, C₁₋₆alkylNR⁶R⁷,

C₀₋₆alkylaryl and C₀₋₆alkylheteroaryl, wherein any C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,

15 C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylheterocycloalkyl, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl may be substituted by one or more A;

R¹ and R² may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A;

20 R³ is independently selected from halogen, nitro, CHO, C₀₋₆alkylCN, OC₁₋₆alkylCN, C₀₋₆alkylOR⁶, OC₁₋₆alkylOR⁶, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C₀₋₆alkylNR⁶R⁷, OC₁₋₆alkylNR⁶R⁷, OC₁₋₆alkylOC₁₋₆alkylNR⁶R⁷, NR⁶OR⁷, C₀₋₆alkylCO₂R⁶, OC₁₋₆alkylCO₂R⁶, C₀₋₆alkylCONR⁶R⁷, OC₁₋₆alkylCONR⁶R⁷, OC₁₋₆alkylNR⁶(CO)R⁷, C₀₋₆alkylNR⁶(CO)R⁷,
 25 O(CO)NR⁶R⁷, NR⁶(CO)OR⁷, NR⁶(CO)NR⁶R⁷, O(CO)OR⁶, O(CO)R⁶, C₀₋₆alkylCOR⁶, OC₁₋₆alkylCOR⁶, NR⁶(CO)(CO)R⁶, NR⁶(CO)(CO)NR⁶R⁷, SR⁶, C₀₋₆alkyl(SO₂)NR⁶R⁷, OC₁₋₆alkylNR⁶(SO₂)R⁷, OC₀₋₆alkyl(SO₂)NR⁶R⁷, C₀₋₆alkyl(SO)NR⁶R⁷, OC₁₋₆alkyl(SO)NR⁶R⁷, SO₃R⁶, C₀₋₆alkylNR⁶(SO₂)NR⁶R⁷, C₀₋₆alkylNR⁶(SO)R⁷, OC₁₋₆alkylNR⁶(SO)R⁷, OC₀₋₆alkylSO₂R⁶, C₀₋₆alkylSO₂R⁶, C₀₋₆alkylSOR⁶, C₁₋₆alkyl,

C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl and C₀₋₆alkylheteroaryl, wherein any C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl and C₀₋₆alkylheteroaryl may be optionally substituted by one or more A;

- R⁶ and R⁷ are independently selected from hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl and C₁₋₆alkylNR⁸R⁹;


R⁶ and R⁷ may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A and wherein a CH₂ group may optionally be replaced by a CO group;

- R⁸ and R⁹ are independently selected from hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl and C₀₋₆alkylheteroaryl;

R⁸ and R⁹ may together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which heterocyclic ring may be optionally substituted by A;


- m is 0, 1, 2, 3 or 4;

R¹⁵ is a group outlined in Scheme I, wherein R¹⁶ and R¹⁷ are hydroxy and B is boron;



- A is halogen, oxo (=O), nitro, CHO, CN, OR⁶, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C₀₋₆alkylNR⁶R⁷, OC₁₋₆alkylNR⁶R⁷, CO₂R⁸, CONR⁶R⁷, NR⁶(CO)R⁶, O(CO)R⁶, COR⁶, SR⁶, (SO₂)NR⁶R⁷, (SO)NR⁶R⁷, SO₃R⁶, SO₂R⁶ or SOR⁶; as a free base or a salt, solvate or solvate of a salt thereof.

A compound of formula XIXa



5 wherein


R^1 and R^2 together forms a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A;

m is 0;

10 A is C_{1-6} alkyl;

as a free base or a salt, solvate or solvate of a salt thereof.

A compound of formula IV



15

wherein

Y is $CONR^5$, NR^5CO , SO_2NR^5 , NR^5SO_2 , CH_2NR^5 , NR^5CONR^5 , CH_2CO , CO or CH_2O ;

X is CH or N;

20 Z is N;

Q is C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl;

R^4 is independently selected from halogen, nitro, CHO, CN, OC_{1-6} alkylCN, OR^6 ,

OC_{1-6} alkyl OR^6 , fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy,

difluoromethoxy, trifluoromethoxy, NR^6R^7 , OC_{1-6} alkyl NR^6R^7 , NR^6OR^7 , CO_2R^6 ,


25 OC_{1-6} alkyl CO_2R^6 , $CONR^6R^7$, OC_{1-6} alkyl $CONR^6R^7$, OC_{1-6} alkyl $NR^6(CO)R^7$, $NR^6(CO)R^7$,

$O(CO)NR^6R^7$, $NR^6(CO)OR^7$, $NR^6(CO)NR^6R^7$, $O(CO)OR^6$, $O(CO)R^6$, COR^6 ,

$\text{OC}_{1-6}\text{alkylCOR}^6$, $\text{NR}^6(\text{CO})(\text{CO})\text{R}^6$, $\text{NR}^6(\text{CO})(\text{CO})\text{NR}^6\text{R}^7$, SR^6 , $(\text{SO}_2)\text{NR}^6\text{R}^7$,
 $\text{OC}_{1-6}\text{alkylNR}^6(\text{SO}_2)\text{R}^7$, $\text{OC}_{0-6}\text{alkyl}(\text{SO}_2)\text{NR}^6\text{R}^7$, $(\text{SO})\text{NR}^6\text{R}^7$, $\text{OC}_{1-6}\text{alkyl}(\text{SO})\text{NR}^6\text{R}^7$,
 SO_3R^6 , $\text{NR}^6(\text{SO}_2)\text{NR}^6\text{R}^7$, $\text{NR}^6(\text{SO})\text{R}^7$, $\text{OC}_{1-6}\text{alkylNR}^6(\text{SO})\text{R}^7$, $\text{OC}_{0-6}\text{alkylSO}_2\text{R}^6$, SO_2R^6 ,
 SOR^6 , $\text{C}_{3-6}\text{cycloalkyl}$, phenyl, a 5 or 6 membered heteroaromatic ring containing one or
5 more heteroatoms independently selected from N, O, or S, or a 5 or 6 membered
heterocyclic ring containing one or more heteroatoms independently selected from N, O, or
S which heterocyclic group may be saturated or unsaturated, and said phenyl ring or 5 or 6
membered heteroaromatic ring or 5 or 6 membered heterocyclic ring may optionally be
fused with a 5 or 6 membered saturated, partially saturated or unsaturated ring containing
10 atoms independently selected from C, N, O or S wherein any $\text{C}_{3-6}\text{cycloalkyl}$, phenyl, 5 or 6
membered heteroaromatic ring with one or two heteroatoms selected independently from
N, O, or S or a 5 or 6 membered heterocyclic ring containing one or two heteroatoms
selected independently from N, O, or S; may be optionally be substituted by one or more
A;
15 R^5 is hydrogen or $\text{C}_{1-6}\text{alkyl}$
 R^6 and R^7 are independently selected from hydrogen, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$,
 $\text{C}_{0-6}\text{alkylC}_{3-6}\text{cycloalkyl}$, $\text{C}_{0-6}\text{alkylaryl}$, $\text{C}_{0-6}\text{alkylheteroaryl}$ and $\text{C}_{1-6}\text{alkylNR}^8\text{R}^9$;
 R^6 and R^7 may together form a substituted 5 or 6 membered heterocyclic ring containing
one or more heteroatoms independently selected from N, O or S, which heterocyclic ring
20 may be optionally substituted by A and wherein a CH_2 group may optionally be replaced
by a CO group;
 R^8 and R^9 are independently selected from hydrogen, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$,
 $\text{C}_{0-6}\text{alkylC}_{3-6}\text{cycloalkyl}$, $\text{C}_{0-6}\text{alkylaryl}$ and $\text{C}_{0-6}\text{alkylheteroaryl}$;
 R^8 and R^9 may together form a 5 or 6 membered heterocyclic ring containing one or more
25 heteroatoms selected from N, O or S, which heterocyclic ring may be optionally
substituted by A;
Hal is halogen;
n is 0, 1, 2, 3 or 4;
A is halogen, oxo (=O), nitro, CHO, CN, OR^6 , $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$,
30 $\text{C}_{0-6}\text{alkylC}_{3-6}\text{cycloalkyl}$, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy,
difluoromethoxy, trifluoromethoxy, $\text{C}_{0-6}\text{alkylNR}^6\text{R}^7$, $\text{OC}_{1-6}\text{alkylNR}^6\text{R}^7$, CO_2R^8 , CONR^6R^7 ,
 $\text{NR}^6(\text{CO})\text{R}^6$, $\text{O}(\text{CO})\text{R}^6$, COR^6 , SR^6 , $(\text{SO}_2)\text{NR}^6\text{R}^7$, $(\text{SO})\text{NR}^6\text{R}^7$, SO_3R^6 , SO_2R^6 or SOR^6 ;

as a free base or a salt, solvate or solvate of a salt thereof.

A compound of formula IV



(IV)

wherein

Y is CONR⁵;

X is N;

10 Z is N;

Q is C₁₋₆alkyl;

R⁴ is independently selected from CN, OR⁶, a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms independently selected from N, O, or S, or a 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O, or S which heterocyclic group may be saturated or unsaturated, wherein any 5 or 6 membered heterocyclic ring containing one or two heteroatoms selected independently from N, O, or S; may be optionally be substituted by A;

R⁵ is hydrogen;


R⁶ is, C₁₋₆alkyl;

20 n is 1;

A is oxo (=O);

as a free base or a salt, solvate or solvate of a salt thereof.

A compound of formula **XXII**



5 wherein:

Z is N;

X is CH or N;

P is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected from N, O or S and said phenyl ring or 5 or 6 membered heteroaromatic ring may
 10 optionally be fused with a 5 or 6 membered saturated, partially saturated or unsaturated ring containing atoms independently selected from C, N, O or S;

R is CHO, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C₀₋₆alkyl(SO₂)NR¹R², OC₀₋₆alkyl(SO₂)NR¹R², OC₁₋₆alkyl(SO)NR¹R², C₁₋₆alkyl(SO)NR¹R², C₀₋₆alkylNR¹(SO)R², OC₁₋₆alkylNR¹(SO)R², C₀₋₆alkylNR¹(SO₂)NR¹R², OC₁₋₆alkylNR¹(SO₂)R²,
 15 C₀₋₆alkyl(SO₂)C₁₋₆alkylNR¹R², OC₀₋₆alkyl(SO₂)C₁₋₆alkylNR¹R², C₀₋₆alkyl(SO)C₁₋₆alkylNR¹R², OC₁₋₆alkyl(SO)C₁₋₆alkylNR¹R², C₀₋₆alkylSC₁₋₆alkylNR¹R², OC₁₋₆alkylSC₁₋₆alkylNR¹R², OC₁₋₆alkylOC₁₋₆alkyl, C₁₋₆alkylOC₁₋₆alkylNR¹R², OC₁₋₆alkylOC₁₋₆alkylNR¹R², C₀₋₆alkylCONR¹⁰R¹¹, OC₀₋₆alkylCONR¹R², OC₁₋₆alkylNR¹R², C₀₋₆alkylNR¹⁰(CO)R¹¹, OC₁₋₆alkylNR¹(CO)R², C₀₋₆alkylNR¹¹(CO)R¹⁰,
 20 C₀₋₆alkylCOR¹¹, OC₁₋₆alkylCOR¹, C₀₋₆alkylNR¹⁰R¹¹, C₀₋₆alkylO(CO)R¹¹, OC₁₋₆alkylO(CO)R¹, C₀₋₆alkylC(NR¹⁰)NR¹⁰R¹¹, C₀₋₆alkylC(NR¹¹)N(R¹⁰)₂, OC₀₋₆alkylC(NR¹)NR¹R², C₀₋₆alkylNR¹⁰(CO)OR¹¹, OC₁₋₆alkylNR¹(CO)OR², C₀₋₆alkylNR¹¹(CO)OR¹⁰, OC₁₋₆alkylCN, NR¹OR², C₀₋₆alkyl(CO)OR⁸, OC₁₋₆alkyl(CO)OR¹, NR¹(CO)NR¹R², NR¹(CO)(CO)R², NR¹(CO)(CO)NR¹R², OR¹² or SO₃R¹;
 25 R¹ and R² are independently selected from hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylheterocycloalkyl, C₁₋₆alkylNR⁶R⁷,

C₀₋₆alkylaryl and C₀₋₆alkylheteroaryl, wherein any C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylheterocycloalkyl, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl may be substituted by one or more A;

R¹ and R² may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A;

R³ is independently selected from halogen, nitro, CHO, C₀₋₆alkylCN, OC₁₋₆alkylCN, C₀₋₆alkylOR⁶, OC₁₋₆alkylOR⁶, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C₀₋₆alkylNR⁶R⁷, OC₁₋₆alkylNR⁶R⁷, OC₁₋₆alkylOC₁₋₆alkylNR⁶R⁷, NR⁶OR⁷, C₀₋₆alkylCO₂R⁶, OC₁₋₆alkylCO₂R⁶, C₀₋₆alkylCONR⁶R⁷, OC₁₋₆alkylCONR⁶R⁷, OC₁₋₆alkylNR⁶(CO)R⁷, C₀₋₆alkylNR⁶(CO)R⁷, O(CO)NR⁶R⁷, NR⁶(CO)OR⁷, NR⁶(CO)NR⁶R⁷, O(CO)OR⁶, O(CO)R⁶, C₀₋₆alkylCOR⁶, OC₁₋₆alkylCOR⁶, NR⁶(CO)(CO)R⁶, NR⁶(CO)(CO)NR⁶R⁷, SR⁶, C₀₋₆alkyl(SO₂)NR⁶R⁷, OC₁₋₆alkylNR⁶(SO₂)R⁷, OC₀₋₆alkyl(SO₂)NR⁶R⁷, C₀₋₆alkyl(SO)NR⁶R⁷, OC₁₋₆alkyl(SO)NR⁶R⁷, SO₃R⁶, C₀₋₆alkylNR⁶(SO₂)NR⁶R⁷, C₀₋₆alkylNR⁶(SO)R⁷, OC₁₋₆alkylNR⁶(SO)R⁷, OC₀₋₆alkylSO₂R⁶, C₀₋₆alkylSO₂R⁶, C₀₋₆alkylSOR⁶, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl and C₀₋₆alkylheteroaryl, wherein any C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl and C₀₋₆alkylheteroaryl may be optionally substituted by one or more A;

R⁶ and R⁷ are independently selected from hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl and C₁₋₆alkylNR⁸R⁹;

R⁶ and R⁷ may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A and wherein a CH₂ group may optionally be replaced by a CO group;

R⁸ and R⁹ are independently selected from hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl and C₀₋₆alkylheteroaryl;

R⁸ and R⁹ may together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which heterocyclic ring may be optionally substituted by A;


R¹⁰ is hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl or C₁₋₆alkylNR⁸R⁹;

R^{11} is C_{1-6} alkylNR⁸R⁹;

R^{10} and R^{11} may together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which heterocyclic ring may be optionally substituted by A;

- 5 A is halogen, oxo (=O), nitro, CHO, CN, OR⁶, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{0-6} alkyl C_{3-6} cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C_{0-6} alkylNR⁶R⁷, OC_{1-6} alkylNR⁶R⁷, CO₂R⁸, CONR⁶R⁷, NR⁶(CO)R⁶, O(CO)R⁶, COR⁶, SR⁶, (SO₂)NR⁶R⁷, (SO)NR⁶R⁷, SO₃R⁶, SO₂R⁶ or SOR⁶;
- m is 0, 1, 2, 3 or 4;
- 10 as a free base or a salt, solvate or solvate of a salt thereof.

A compound of formula **XXII**



(XXII)

15

wherein:

Z is N;

X is N;

P is phenyl;

- 20 R is C_{0-6} alkyl(SO₂)NR¹R²;

R^1 and R^2 may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S;

m is 0;

as a free base or a salt, solvate or solvate of a salt thereof.

25

In yet another aspect of the invention the following compounds, which are useful as intermediates in the preparation of compounds of formula I, are provided:

- 1-[(4-Bromophenyl)sulfonyl]pyrrolidine;
4-(Pyrrolidin-1-ylsulfonyl)phenylboronic acid;
5 4-[(4-Methylpiperazin-1-yl)sulfonyl]phenylboronic acid;
3-Amino-6-bromo-*N*-(2-morpholin-4-ylethyl)pyrazine-2-carboxamide;
3-Amino-6-bromo-*N*-[2-(1*H*-imidazol-4-yl)ethyl]pyrazine-2-carboxamide;
3-Amino-6-bromo-*N*-[3-(1*H*-imidazol-1-yl)propyl]pyrazine-2-carboxamide;
3-Amino-6-bromo-*N*-(2-thien-2-ylethyl)pyrazine-2-carboxamide;
10 3-Amino-6-bromo-*N*-(thien-2-ylmethyl)pyrazine-2-carboxamide;
3-Amino-6-bromo-*N*-(2-methoxyethyl)pyrazine-2-carboxamide;
3-Amino-6-bromo-*N*-(3-methoxypropyl)pyrazine-2-carboxamide;
3-Amino-6-bromo-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]pyrazine-2-carboxamide;
3-Amino-6-bromo-*N*-(cyanomethyl)pyrazine-2-carboxamide;
15 Methyl 3-amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate;
Methyl 3-[[2,6-dimethoxy-4-(2-phenylethoxy)benzyl]amino]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate polystyrene;
3-[[2,6-Dimethoxy-4-(2-phenylethoxy)benzyl]amino]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylic acid polystyrene;
20 as a free base or a salt, solvate or solvate of a salt thereof.

Listed below are definitions of various terms used in the specification and claims to describe the present invention.

- 25 For the avoidance of doubt it is to be understood that where in this specification a group is qualified by 'hereinbefore defined', 'defined hereinbefore', 'is as defined above' or 'are as defined above' the said group encompasses the first occurring and broadest definition as well as each and all of the preferred definitions for that group.
- 30 For the avoidance of doubt it is to be understood that in this specification 'C₀₋₆' means a carbon group having 0, 1, 2, 3, 4, 5 or 6 carbon atoms.

The term "alkyl" as used herein includes both straight and branched chain alkyl groups. C₁₋₆alkyl may be methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, neo-pentyl, hexyl.

- 5 The term "C₃₋₆ cycloalkyl" as used herein refers to a monocyclic hydrocarbon ring system having 3 to 6 carbon atoms. C₃₋₆ cycloalkyl may be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.

- 10 The term "alkoxy" as used herein, unless stated otherwise includes "alkyl"O groups in which "alkyl" is as hereinbefore defined. C₁₋₆alkoxy may be methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy, n-pentyloxy, i-pentyloxy, t-pentyloxy, neo-pentyloxy, hexyloxy.

- 15 The term "alkenyl" as used herein includes both straight and branched chain alkenyl groups but references to individual alkenyl groups such as 2-butenyl is specific for the straight chain version only. C₂₋₆ alkenyl may be, but are not limited to, vinyl, allyl, propenyl, i-propenyl, butenyl, i-butenyl, crotyl, pentenyl, i-pentenyl or hexenyl.

- 20 The term "alkynyl" as used herein includes both straight and branched chain alkynyl groups but references to individual alkynyl groups such as 2-butyne are specific for the straight chain version only. C₂₋₆ alkynyl may be, but are not limited to, ethynyl, propargyl, butynyl, i-butyne, pentynyl, i-pentynyl or hexynyl.

- 25 In this specification, unless stated otherwise, the term "aryl" refers to an optionally substituted monocyclic or bicyclic hydrocarbon ring system containing at least one aromatic ring. The "aryl" may be fused with a C₅₋₇cycloalkyl ring to form a bicyclic hydrocarbon ring system. Examples and suitable values of the term "aryl" are phenyl, naphthyl, indanyl or tetralinyl.

- 30 In this specification, unless stated otherwise, the terms "heteroaryl" and "5 or 6 membered heteroaromatic ring" containing one or more heteroatoms selected from N, O and S may

be, but are not limited to, furyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl or thienyl.

In this specification, unless stated otherwise, the term "5 or 6 membered, saturated, partly
5 saturated or unsaturated ring containing atoms independently selected from C, N, O or S" may be, but are not limited to, furyl, isoxazolyl, isothiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, thienyl, imidazolyl, imidazolidinyl, imidazolinyl, morpholinyl, piperazinyl, piperidyl, piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, thiomorpholinyl,
10 cyclohexyl or cyclopentyl.

In this specification, unless stated otherwise, the term "5 or 6 membered heteroaromatic ring containing one or more heteroatoms independently selected from N, O, or S" may be, but are not limited to, furyl, isoxazolyl, isothiazolyl, oxazolyl, pyrazinyl, pyrazolyl,
15 pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, thienyl or imidazolyl.

In this specification, unless stated otherwise, the term "5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O, or S" may be, but are not limited to, imidazolidinyl, imidazolinyl, morpholinyl, piperazinyl, piperidyl, piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl or
20 thiomorpholinyl.

In this specification, unless stated otherwise, the term halogen may be fluorine, chlorine, bromine or iodine. The term Hal in the formulas means halogen.

25

The present invention relates to the use of compounds of formula I as hereinbefore defined as well as to the salts, solvates and solvates of salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula I.

30

Both organic and inorganic acids can be employed to form non-toxic pharmaceutically acceptable acid addition salts of the compounds, e.g. hydrochlorides, of this invention. In

addition, a suitable pharmaceutically acceptable salt of the compounds of the invention, which is sufficiently acidic is an alkali metal salt, an alkaline earth metal salt or a salt with an organic base, which affords a physiologically-acceptable cation.

5 It will be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It is to be understood that the present invention encompasses all such solvated forms which possess the above-mentioned activity.

10 Some compounds of formula I may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess GSK3 inhibitory activity.

It is to be understood that the present invention relates to any and all tautomeric forms of
15 the compounds of formula I.

An object of the invention is to provide compounds of formula I for therapeutic use, especially compounds that are useful for the prevention and/or treatment of conditions associated with glycogen synthase kinase-3 (GSK3) in mammals
20 including man. Particularly, compounds of formula I exhibiting a selective affinity for GSK-3.

METHODS OF PREPARATION

25

Another aspect of the present invention provides a process for preparing a compound of formula I as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.


Throughout the following description of such processes it is understood that, where
30 appropriate, suitable protecting groups will be added to, and subsequently removed from, the various reactants and intermediates in a manner that will be readily understood by one

skilled in the art of organic synthesis. Conventional procedures for using such protecting groups as well as examples of suitable protecting groups are described, for example, in "Protective Groups in Organic Synthesis" T.W. Green, P.G.M. Wuts, Wiley-Interscience, New York, 1999.


5

Methods of preparation of the intermediates

The process for the preparation of the intermediates, wherein Y, X, Z, P, Q, R, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², A, m and n are, unless specified otherwise, defined as in formula I, comprises of:




- (i) halogenation of a compound of formula II, wherein Z is N and X are N or CH, Hal is halogen, R¹³ is hydrogen, C₁₋₆alkyl or when R¹³ is hydrogen in the form of a salt such as a sodium salt, to obtain a compound of formula III, may be carried out using a suitable
 15 halogenating reagent such as iodine, bromine, chlorine, halide salts e.g. ICl, BrCl or HOCl or other suitable halogenation reagents such as *N*-bromosuccinimide or phosphorous tribromide. The reaction may be catalysed by metals or acids such as Fe, Cu-salts, acetic acid or sulfuric acid or aided by oxidising agents such as nitric acid, hydrogen peroxide or sulfur trioxide. The reaction may be carried out in a suitable solvent such as water, acetic
 20 acid or chloroform at a temperature in the range of -70 °C to +100 °C.




(ii) amidation of a compound of formula **III**, wherein Z is N and X are N, Hal is halogen, R¹³ is


C₁₋₆alkyl to obtain a compound of formula **IV**, wherein Y is CONR⁵ and Q, R⁴ and n are as defined above, may be carried out by treating a compound of formula **III** with the
 5 appropriate amine such as a compound of formula **V** wherein Q, R⁴, R⁵ and n are as defined above. The reaction may be performed neat or using a suitable solvent such as *N,N*-dimethylformamide, methylene chloride or ethyl acetate at a temperature ranging from -25 °C to +150 °C. The reaction may be aided by using a base such as potassium carbonate, triethylamine or 1,8-diazabicyclo[5.4.0]undec-7-ene or an acid such as
 10 trimethylaluminum or *p*-toulenesulfonic acid.




(iii) amidation of a compound of formula **III**, wherein R¹³ is hydrogen, to obtain a compound of formula **IV**, wherein Y is CONR⁵ and R⁴ is a substituents that is not
 15 susceptible to certain coupling agents, may be performed by activation of a compound of formula **III** by treating the compound with coupling reagents such as 1,3-diisopropylcarbodiimide, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, 1,3-dicyclohexylcarbodiimide, O-(benzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium tetrafluoroborate, O-(benzotriazol-1-yl)-*N, N, N', N'*-
 20 tetramethyluronium hexafluorophosphate, 1,1'-carbonyldiimidazole or *O*-(7-azabenzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium hexafluorophosphate where the reaction may be aided by the addition of 1-hydroxybenzotriazole hydrate, or using an acyl halide reagent such as cyanuric chloride, oxalyl chloride, thionyl chloride or bromotrispyrrolidinophosphonium hexafluorophosphate, followed by treatment with the
 25 appropriate amine such as a compound of formula **V** wherein Q, R⁴, R⁵, and n are as defined above, in a suitable solvent such as methylene chloride chloroform, acetonitrile or tetrahydrofuran and at a rection temperature between 0 °C and reflux. The reaction may be aided by using a base such as potassium carbonate or a trialkyl amine e.g triethyl amine or *N*-ethyl-*N,N*-diisopropyl amine.



(iv) halogenating a compound of formula VI, wherein R^{14} is halogen e.g. bromine or chlorine or $\text{CH}_3(\text{CO})\text{NH}$ and P, R^3 and m are as defined above, to obtain a compound of formula VII may be carried out by treatment of a compound of formula VI with a halogenation reagents such as thionyl chloride or oxalyl chloride. The reaction may be performed neat or in a suitable solvent such as tetrahydrofuran, dioxane, *N,N*-dimethylformamide or methylene chloride at a temperature range between -20°C and $+60^\circ\text{C}$;




(v) amidation of a compound of formula VII, wherein R^{14} is halogen e.g. bromine or chlorine or $\text{CH}_3(\text{CO})\text{NH}$, Hal is fluorine, chlorine or bromine and P, R^3 and m are as defined above, to obtain a compound of formula VIII, wherein R^{14} is bromine or $\text{CH}_3(\text{CO})\text{NH}$ and P, R^1 , R^2 , R^3 and n are as defined above, may be carried out by reacting a compound of formula VII with the suitable amine HNR^1R^2 . The reaction may be performed in a suitable solvent such as tetrahydrofuran, dioxane, *N,N*-dimethylformamide or methylene chloride in a temperature range between 0°C and $+50^\circ\text{C}$.




(vi) conversion of a compound of formula IX, wherein P, R^3 and m are as defined above, to obtain a compound of formula XII, wherein P, R^1 , R^2 , R^3 and n are as defined above, may

be carried out by treating a compound of formula **IX** with a sulfonating reagent such as chloro sulfonic acid followed by addition of a suitable amine, HNR^1R^2 . The reaction may be performed neat or in an appropriate solvent such as tetrahydrofuran or methylene chloride and at a reaction temperature between +25 °C and reflux.

5




- (vii) transformation of a compound of formula **VIII**, wherein R^{14} is $\text{CH}_3(\text{CO})\text{NH}$, and R^1 , R^2 , R^3 , m and P are as defined above, to a compound of formula **XII** may be carried out by the reaction with an acid such as hydrochloric acid or hydrobromic acid at a temperature range between +25 °C and +110 °C.




- (viii) conversion of a compound of formula **XII** to obtain a compound of formula **VIII**, wherein R^{14} is bromine, R^1 , R^2 , R^3 , m and P are as defined above, may be carried out by treatment of a compound of formula **XII** with sodium nitrite and hydrobromic acid followed by the addition of a bromide source such as CuBr in an appropriate solvent such as water at a temperature range between 0 °C and +5 °C.

20




(ix) formation of an amide of formula XV, wherein R^{10} , R^{11} , R^3 , m and P are as defined above, may be carried out by treating a compound of formula XIV, wherein R^{13} is C_{1-6} alkyl, with the appropriate amine $HNR^{10}R^{11}$. The reaction may be performed neat or using a suitable solvent such as *N,N*-dimethylformamide, methylene chloride or ethyl acetate at a temperature ranging from $-25\text{ }^{\circ}\text{C}$ to $+150\text{ }^{\circ}\text{C}$. The reaction may be aided by using a base such as potassium carbonate, triethyl amine or 1,8-diazabicyclo[5.4.0]undec-7-ene or an acid such as trimethylaluminum or *p*-toulenesulfonic acid.

(x) amidation of a compound of formula XIV, wherein R^{13} is hydrogen and R^3 , m and P are as defined above to obtain a compound of formula XV may be performed by activation of a compound of formula XIV by treating the compound with coupling reagents such as 1,3-diisopropylcarbodiimide, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, 1,3-dicyclohexylcarbodiimide, *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate, *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate, 1,1'-carbonyldiimidazole or *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate where the reaction may be aided by the addition of 1-hydroxybenzotriazole hydrate, or using an acyl halide reagent such as cyanuric chloride, oxalyl chloride, thionyl chloride or bromotrispyrrolidinophosphonium hexafluorophosphate, followed by treatment with the appropriate amine $HNR^{10}R^{11}$. The reaction may be carried out in a suitable solvent such as *N,N*-dimethylformamide, acetonitrile or methylene chloride at a temperature ranging from $-25\text{ }^{\circ}\text{C}$ to $+150\text{ }^{\circ}\text{C}$, with or without a suitable base such as an alkyl amine e.g. triethyl amine, *N*-ethyl-*N,N*-diisopropyl amine or *N*-methyl morpholine, or potassium carbonate or sodium hydroxide.




(xi) bromination of a compound of formula **XVI** to obtain a compound of formula **XV**, wherein R^{10} , R^{11} , R^3 , m and P are as defined above, may be carried out by treatment of a compound of formula **XVI** with bromine with or without an appropriate base such as sodium acetate in a suitable solvent such as acetic acid.

5



(xii) conversion of a compound of formula **XVII**, wherein R^3 , m and P are as defined above, to obtain a compound of formula **XVIII**, wherein R^1 , R^2 , R^3 , m , C_{1-6} alkyl and P are as defined above, may be carried out by reacting a compound of formula **XVII** with a suitable alcohol, $R^1R^2NC_{1-6}\text{alkylOH}$ in the presence of triphenylphosphine and an appropriate azidodicarboxylate such as diethyl azidodicarboxylate. The reaction may be performed in a suitable solvent such as tetrahydrofuran, toluene or methylene chloride and at a reaction temperature between 0 °C to +60 °C.

15





(xiii) borylation of a compounds of formula **VIII** wherein R^{14} is halogen e.g. bromine, **XV** and **XVIII** to obtain compounds of formula **XIXa-c** (**XIXa** from **VIII**, **XIXb** from **XVIII** and **XIXc** from **XV**), wherein R^{15} , R^1 , R^2 , R^3 , R^{10} , R^{11} , m , C_{1-6} alkyl and P are as defined above and R^{15} may be a group outlined in Scheme I, wherein B is boron, R^{16} and R^{17} are C_{1-6} alkoxy or hydroxy, or C_{1-3} alkoxy fused together to form a 5 or 6 membered cyclic boron-oxygen- C_{2-3} alkyl species and the alkoxy, the aryl group or 5 or 6 membered cyclic

20


boron-oxygen-C₂₋₃alkyl species may be optionally substituted, may be carried out by a reaction with:

- a) butyllithium or magnesium and a suitable boron compound such as trimethyl borate or triisopropyl borate. The reaction may be performed in a suitable solvent such as tetrahydrofuran, hexane or methylene chloride in a temperature range between
 5 -78 °C and +20 °C;
- or,
- b) a palladium catalyst such as palladium tetrakis(triphenylphosphine), palladium diphenylphosphineferrocene dichloride or palladium acetate with or without a suitable
 10 ligand such as 2-(dicyclohexylphosphino)biphenyl, and a suitable boron species such as bis(catecholato)diboron, bis(pinacolato)diboron or pinacolborane. A suitable base, which under the reaction conditions do not promote dimerisation of compounds of formula XIXa-c, such as a tertiary amine such as triethyl amine or diisopropylethyl amine or potassium acetate may be used. The reaction may be performed in a solvent such as dioxane, toluene
 15 or acetonitrile at temperatures between +80 °C and +100 °C.



- (xiv) conversion of a compound of formula III to a compound of formula XX, wherein,
 20 R¹³ is C₁₋₆alkyl and X, Z, R, R³, P and m are as defined above, may be carried out by a de-halogen coupling with a suitable compound of formula XIXa-c.


The reaction may be carried out by coupling of a compound of formula **III** with an appropriate aryl boronic acid or a boronic ester of formula **XIXa-c** (the boronic acid or boronic ester may be formed in situ using the compounds of formula **VIII** wherein R^{14} is halogen e.g. bromine, **XV** and **XVIII** and conditions described in (xiii)). The reaction may be carried out using a suitable palladium catalyst such as $Pd(PPh_3)_4$, $Pd(dppf)Cl_2$ or $Pd(OAc)_2$ with or without a suitable ligand such as $P(tert-butyl)_3$ or 2-(dicyclohexylphosphino)biphenyl or a nickel catalyst such as nickel on charcoal or $Ni(dppe)Cl_2$ together with Zn and sodium triphenylphosphinetrimetasulfonate. A suitable base such as an alkyl amine e.g. triethyl amine, or potassium carbonate, sodium carbonate, sodium hydroxide or cesium fluoride may be used in the reaction, which is performed in a temperature range between +20 °C and +160 °C using an oil bath or a microwave oven in a suitable solvent or solvent mixture such as toluene, tetrahydrofuran, dimethoxyethane/water or *N,N*-dimethylformamide.



(xv) conversion of a compound of formula **XX**, wherein R^{13} is C_{1-6} alkyl and R , R^3 , X , Z and m are as defined above, to a compound of formula **XXI** may be carried out by reaction with a suitable solid phase reagent such as a formyl polystyrene e.g. 2-(3,5-dimethoxy-4-formylphenoxy)ethyl polystyrene or 2-(4-formyl-3-methoxyphenoxy)ethyl polystyrene in a suitable solvents such as *N,N*-dimethylformamide or methylene chloride in the presence of a suitable acid e.g. acetic acid and a suitable reducing reagent such as sodium triacetoxy borohydride or sodium cyanoborohydride at a suitable reaction temperature ranging

between 0 °C and +50 °C. The reaction may be aided by the presence of trimethylsilyl chloride.

5



(XXII)

(xvi) hydrolysis of a compound of formula **XXI**, wherein R, R³, X, Z and m are as defined above, to a compound of formula **XXII** may be carried out in a suitable solvent such as water, tetrahydrofuran or mixtures thereof in the presence of a suitable base such as sodium hydroxide, potassium hydroxide or lithium hydroxide at a suitable reaction temperature ranging between +25 °C and reflux.

15


Methods of preparation of end products

Another object of the invention are processes for the preparation of a compound of general formula **I**, wherein Y, X, Z, P, Q, R, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², A, m and n are, unless specified otherwise, defined as in formula **I**, comprising of:

20

A

De-halogen coupling, wherein R³ and R⁴ are substituents that are not susceptible to certain agents in the reaction, of a compound of formula **IV** with an appropriate aryl species to give a compound of formula **I**:



(IV)

(I)


Thus, the de-halogen coupling according to process A may be carried out by coupling of a compound of formula IV with:

- 5 a) an appropriate aryl halogen such as aryl iodide, aryl bromide or aryl chloride in the presence of metals such as copper, nickel or zinc and nickel complexes, copper oxide or palladium acetate and tetrabutylammonium bromide and a base such as potassium carbonate or triethylamine. The reaction may occur at a temperature between 20 °C and 180 °C in a suitable solvent such as *N,N*-dimethylformamide, toluene or 2-pentanol;
- 10 or,
- b) an appropriate aryl boronic acid or a boronic ester such as compounds of formula XIXa-c (the boronic acid or boronic ester may be formed in situ using the compounds of formula VIII wherein R¹⁴ is halogen e.g. bromine, XV and XVIII and conditions described in (xiii)). The reaction may be carried out using a suitable palladium catalyst such as
- 15 Pd(PPh₃)₄, Pd(dppf)Cl₂ or Pd(OAc)₂ with or without a suitable ligand such as P(*tert*-butyl)₃ or 2-(dicyclohexylphosphino)biphenyl or a nickel catalyst such as nickel on charcoal or Ni(dppe)Cl₂ together with Zn and sodium triphenylphosphinetrimetasulfonate. A suitable base such as an alkyl amine e.g. triethyl amine, or potassium carbonate, sodium carbonate,
- 20 sodium hydroxide or cesium fluoride may be used in the reaction, which is performed in the temperature range between +20 °C and +160 °C using an oil bath or in a microwave oven in a suitable solvent or solvent mixture such as toluene, tetrahydrofuran, dimethoxyethane/water or *N,N*-dimethylformamide.;
- or,
- 25 c) an appropriate aryl stannane in the presence of palladium catalyst such as Pd(PPh₃)₄, Pd(PPh₃)₂Cl₂ or Pd(dba)₃ and if needed a helping reagent such as 4-*tert*-butylcatechol, lithium chloride or potassium carbonate. Suitable solvents may be toluene, tetrahydrofuran or *N,N*-dimethylformamide. The reaction may occur in a temperature range of +20 °C and +120 °C.

B

Amidation, wherein R^3 and R^4 are substituents that are not susceptible to certain agents in the reaction, of a compound of formula **XXII** with the appropriate amine:

5



Thus, the amidation of a compound of formula **XXII**, may be performed by activation of a
 10 compound of formula **XXII** by treating the compound with coupling reagents such as 1,3-
 diisopropylcarbodiimide, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride,
 1,3-dicyclohexylcarbodiimide, O-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium
 tetrafluoroborate, O-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium
 hexafluorophosphate, 1,1'-carbonyldiimidazole or O-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-
 15 tetramethyluronium hexafluorophosphate where the reaction may be aided by the addition
 of 1-hydroxybenzotriazole hydrate, or using an acyl halide reagent such as cyanuric
 chloride, oxalyl chloride, thionyl chloride or bromotrispyrrolidinophosphonium
 hexafluorophosphate followed by treatment with the appropriate amine such as a
 compound of formula **V** followed by,
 20 cleavage of the solid phase moiety by treatment with an suitable acid such as
 trifluoroacetic acid in a suitable solvent such as methylene chloride or chloroform and at a
 reaction temperature between 0 °C and reflux to give the compound of formula **(I)**.

The hydrochloric salt of compound of formula **I** may be obtained from a compound of
 25 formula **I** by treatment with hydrochloric acid at a temperature range between 0 °C and

+25 °C, in suitable solvent such as methylene chloride, tetrahydrofuran, diethyl ether or methylene chloride/methanol mixture.

WORKING EXAMPLES

5

Example 1

1-[(4-Bromophenyl)sulfonyl]pyrrolidine

Pyrrolidine (2.5 g, 35.2 mmol) was added to a solution of 4-bromobenzenesulfonyl chloride (4.5 g, 17.6 mmol) in methylene chloride (10 mL) at 0 °C. The mixture was stirred for 2 h and an aqueous sodium hydroxide solution (1 M, 5 mL) was added and stirring was continued for another 10 min. The organic phase was separated and diluted with methylene chloride (40 mL), washed with aqueous HCl (1 M, 10 mL), and water (2x10 mL). The organic phase was dried (sodium sulphate) and the solvent was evaporated. The title compound was isolated in 5.0 g (98% yield) as a white solid: ¹H NMR (CDCl₃, 400 MHz) δ 7.65 (m, 4 H), 3.20 (m, 4 H), 1.74 (m, 4 H); ¹³C NMR (CDCl₃, 100 MHz) δ 135.93, 132.17, 128.84, 127.39, 47.84, 25.13; MS (ES) *m/z* 290 and 292 (M⁺+1).

15

Example 2

4-(Pyrrolidin-1-ylsulfonyl)phenylboronic acid

n-Butyllithium (20 mL, 31 mmol) was added dropwise over 30 min to a cooled (-78 °C) solution of 1-[(4-bromobenzenesulfonyl)pyrrolidine] (3.0 g, 10.3 mmol) and triisopropyl borate (7.2 mL, 30.9 mmol) in anhydrous tetrahydrofuran (10 mL) under a nitrogen atmosphere. The reaction mixture was stirred for 1 h at -78 °C whereafter the temperature was allowed to reach room temperature over 3 h. Silica gel was added and the solvent was evaporated. Chromatography on a silica gel column using a gradient methylene chloride (100%) to methylene chloride/ethanol, (1:1), gave 1.85 g (70% yield) of the title compound as a white solid: ¹H NMR (CD₃OD, 400 MHz) δ 7.90 (d, *J* = 7 Hz, 2 H), 7.75 (d, *J* = 8 Hz, 2 H), 3.21 (m, 4 H), 1.72 (m, 4 H); ¹³C NMR (CDCl₃/CD₃OD (1:1), 100 MHz) δ 136.79, 133.50, 125.48, 47.19, 24.30; MS (ES) *m/z* 256 (M⁺+1).

25

Example 3

4-[(4-Methylpiperazin-1-yl)sulfonyl]phenylboronic acid

30

Triisopropyl borate (0.64 mL, 2.8 mmol) was added to a solution of 1-[(4-bromophenyl)sulfonyl]-4-methylpiperazine (0.602 g, 1.9 mmol; described: in Keasling, H. H. et al. *J. Med. Chem.* **1965**, 8, 548-550) in anhydrous tetrahydrofuran (7 mL) at -78 °C under a nitrogen atmosphere followed by dropwise addition of *n*-butyllithium (1.4 mL, 2.2 mmol). The resulting mixture was stirred at -78 °C for 2 h and at room temperature for another 16 h. Water (2.0 mL) was added and the mixture stirred for 30 min and evaporated to dryness. The residue was pre-adsorbed onto silica and purified by column chromatography on silica using methylene chloride/methanol, (9:1 to 1:9), as the eluent. The product was re-crystallized from water to give 311 mg (58% yield) of the title compound as white crystals: mp 215-218 °C; ¹H NMR (DMSO-d₆, 400 MHz) δ 8.47 (br s, 2 H), 8.05 (d, *J* = 8 Hz, 2 H), 7.73 (d, *J* = 8 Hz, 2 H), 3.77 (m, 2 H), 3.40 (m, 2 H), 3.13 (m, 2 H), 2.71 (s, 3 H), 2.65 (m, 2 H); ¹³C NMR (DMSO-d₆, 100 MHz) δ 133.7, 133.3, 124.7, 49.8, 41.6, 41.4; MS (TSP) *m/z* 285 (M⁺+1).

Example 4

3-Amino-6-bromo-*N*-(2-morpholin-4-ylethyl)pyrazine-2-carboxamide

1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.68 g, 3.5 mmol) was added in one portion to a stirred suspension of 2-morpholin-4-ylethanamine (0.422 g, 3.2 mmol), 3-amino-6-bromopyrazine-2-carboxylic acid (0.64 g, 3.0 mmol; described in: Ellingson, R. C.; Henry, R. L. *J. Am. Chem. Soc.* **1949**, 2798-2800), and 1-hydroxybenzotriazole hydrate (0.48 g, 3.5 mmol) in acetonitrile (25 mL) at 0 °C. The cooling bath was removed and stirring was continued at room temperature for 7 h. The solid was filtered off, washed with acetonitrile and purified by column chromatography on silica using methylene chloride/methanol/triethyl amine, (95:5:0.1), to give 0.68 g (69% yield) of the title compound: ¹H NMR (DMSO-d₆, 400 MHz) δ 8.53 (m, 1 H), 8.34 (s, 1 H), 8.68 (br s, 2 H), 3.57 (t, *J* = 5 Hz, 4 H), 3.37 (q, *J* = 7 Hz, 2 H), 2.47 (q, *J* = 7 Hz, 2 H), 2.40 (m, 4 H); MS (ES) *m/z* 330 and 332 (M⁺+1).

Example 5

3-Amino-6-bromo-*N*-[2-(1*H*-imidazol-4-yl)ethyl]pyrazine-2-carboxamide

The title compound was prepared as described for Example 4 using histamine. Yield: 18%: ¹H NMR (DMSO-d₆, 400 MHz) δ 11.87 (br s, 1 H), 8.80 (m, 1 H), 8.34 (s, 1 H), 7.72 (br s,

2 H), 7.55 (s, 1 H), 6.83 (s, 1 H), 3.49 (q, $J = 7$ Hz, 2 H), 2.75 (t, $J = 7$ Hz, 2 H); MS (ES) m/z 311 and 313 ($M^+ + 1$).

Example 6

5 3-Amino-6-bromo-*N*-[3-(1*H*-imidazol-1-yl)propyl]pyrazine-2-carboxamide

The title compound was prepared as described for Example 4 using 3-(1*H*-imidazol-1-yl)propan-1-amine. Yield: 67%; ^1H NMR (DMSO- d_6 , 400 MHz) δ 8.72 (m, 1 H), 8.34 (s, 1 H), 7.71 (br s, 2 H), 7.65 (s, 1 H), 7.20 (s, 1 H), 6.88 (s, 1 H), 3.98 (t, $J = 7$ Hz, 2 H), 3.24 (q, $J = 6$ Hz, 2 H), 1.95 (quin, $J = 7$ Hz, 2 H); MS (ES) m/z 325 and 327 ($M^+ + 1$).

10

Example 7

3-Amino-6-bromo-*N*-(2-thien-2-ylethyl)pyrazine-2-carboxamide

A solution of 3-amino-6-bromopyrazine-2-carboxylic acid (0.50 g, 2.3 mmol; described in: Ellingson, R. C.; Henry, R. L. *J. Am. Chem. Soc.* **1949**, 2798-2800), 1-

15 hydroxybenzotriazole hydrate (0.41 g, 2.7 mmol) in acetonitrile (5 mL) were added to a stirred solution of 2-thien-2-ylethanamine (0.32 g, 2.5 mmol) in acetonitrile (5 mL) followed by addition of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.52 g, 2.7 mmol) and acetonitrile (1.5 mL). The resulting mixture was stirred at room temperature over night and the solvent was evaporated. The residue was re-crystallized
20 from acetonitrile and subsequently from methanol to give 0.5 g (66% yield) of the title compound: ^1H NMR (DMSO- d_6 , 400 MHz) δ 8.73 (t, $J = 6$ Hz, 1 H), 8.34 (s, 1 H), 7.71 (br s, 2 H), 7.34 (dd, $J = 5$, 1 Hz, 1 H), 6.95 (d, $J = 3$ Hz, 1 H), 6.91 (m, 1 H), 3.50 (q, $J = 7$ Hz, 2 H), 3.05 (t, $J = 7$ Hz, 2 H); MS (ES) m/z 327 and 329 ($M^+ + 1$).

25 The following Examples, 8 – 12, were synthesized as described for Example 7.

Example 8

3-Amino-6-bromo-*N*-(thien-2-ylmethyl)pyrazine-2-carboxamide

Starting material: 1-thien-2-ylmethanamine. Purification by re-crystallization from

30 methanol gave the title compound. Yield: 73%; ^1H NMR (DMSO- d_6 , 400 MHz) δ 9.20 (t, $J = 6$ Hz, 1 H), 8.35 (s, 1 H), 7.72 (br s, 2 H), 7.37 (dd, $J = 5$, 1 Hz, 1 H), 7.01 (dd, $J = 3$, 1

Hz, 1 H), 6.95 (dd, $J = 5, 3$ Hz, 1 H), 4.59 (d, $J = 6$ Hz, 2 H); MS (ES) m/z 313 and 315 ($M^+ + 1$).

Example 9

5 **3-Amino-6-bromo-*N*-(2-methoxyethyl)pyrazine-2-carboxamide**

Starting material: 2-methoxyethylamine. Purification by re-crystallization from methanol gave the title compound. Yield: 77%: ^1H NMR (DMSO- d_6 , 400 MHz) δ 8.51 (s, 1 H), 8.36 (s, 1 H), 7.73 (br s, 2 H), 3.45 (s, 4 H), 3.27 (s, 3 H); MS (ES) m/z 275 and 277 ($M^+ + 1$).

10 **Example 10**

3-Amino-6-bromo-*N*-(3-methoxypropyl)pyrazine-2-carboxamide

Starting material: 2-methoxypropylamine. Purification by re-crystallization from methanol gave the title compound. Yield: 42%: ^1H NMR (DMSO- d_6 , 400 MHz) δ : 8.64 (m, 1 H), 8.33 (s, 1 H), 7.70 (br s, 2 H), 3.37 (t, $J = 6$ Hz, 2 H), 3.31 (t, $J = 7$ Hz, 2 H), 3.24 (s, 3 H),
15 1.75 (quin, $J = 7$ Hz, 2 H); MS (ES) m/z 289 and 291 ($M^+ + 1$).

Example 11

3-Amino-6-bromo-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]pyrazine-2-carboxamide

Starting material: 1-(3-aminopropyl)-2-pyrrolidinone. Purification by column
20 chromatography on silica using methylene chloride/methanol/triethyl amine, (98:2:0.1), gave the title compound. Yield: 89%: ^1H NMR (DMSO- d_6 , 400 MHz) δ 8.65 (s, 1 H), 8.36 (s, 1 H), 7.73 (br s, 2 H), 3.36 (m, 2 H), 3.22 (m, 4 H), 2.23 (m, 2 H), 1.93 (m, 2 H), 1.70 (m, 2 H); MS (ES) m/z 342 and 344 ($M^+ + 1$).

25 **Example 12**

3-Amino-6-bromo-*N*-(cyanomethyl)pyrazine-2-carboxamide

Starting material: aminoacetonitril. Purification by re-crystallization from methanol gave the title compound. Yield: 47%: ^1H NMR (DMSO- d_6 , 400 MHz) δ 9.21 (t, $J = 6$ Hz, 1 H), 8.41 (s, 1 H), 7.70 (br s, 2 H), 4.25 (d, $J = 6$ Hz, 2 H).

Example 13**3-Amino-*N*-(2-morpholin-4-ylethyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide hydrochloride**

5 *n*-Butyllithium (1.6 mL, 2.6 mmol) was added dropwise over 10 min to a cooled solution (-78 °C) of triisopropyl borate (0.6 mL, 2.6 mmol), and 1-[(4-bromophenyl)sulfonyl]pyrrolidine (0.251 g, 0.86 mmol) in anhydrous tetrahydrofuran (10 mL) under an atmosphere of nitrogen. The resulting mixture was stirred at -78 °C for 1 h and the mixture was allowed to warm up to room temperature. Aqueous HCl (3 M, 1.4 mL, 10 4.3 mmol) was added and the mixture was stirred for 10 min followed by the addition of sodium carbonate (0.9 g, 8.6 mmol) and the stirring was continued for another 20 min. 3-Amino-6-bromo-*N*-(2-morpholin-4-ylethyl)pyrazine-2-carboxamide (0.20 g, 0.61 mmol), and tetrahydrofuran (4 mL) were added followed by addition of Pd(dppf)Cl₂ (28 mg, 0.03 mmol) and the resulting mixture was heated at 65 °C for 17 h. The mixture was allowed to 15 return to room temperature and the solvent was evaporated. The resulting residue was suspended in methanol, silica was added, and the solvent was evaporated. Purification by column chromatography on silica using methylene chloride/methanol/triethyl amine, (95:5:0.1), as the eluent gave the free base that was subsequently dissolved in hot methanol and treated with HCl (1 M in diethyl ether). The formed precipitate was filtered off and 20 dried in vacuo to give 72 mg (26% yield) of the title compound as a yellow solid: ¹H NMR (DMSO-d₆, 400 MHz) δ 11.24 (br s, 1 H), 9.28 (m, 1 H), 8.98 (s, 1 H), 8.49 (d, *J* = 8 Hz, 2 H), 7.83 (d, *J* = 8 Hz, 2 H), 3.97 (m, 2 H), 3.87 (d, *J* = 12 Hz, 2 H), 3.78 (m, 2 H), 3.55 (d, *J* = 12 Hz, 2 H), 3.15 (m, 6 H), 1.65 (m, 4 H); MS (ES) *m/z* 461 (*M*⁺+1).

Example 14**3-Amino-*N*-[2-(1*H*-imidazol-4-yl)ethyl]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide hydrochloride**

The title compound was prepared as described for Example 13 using 3-amino-6-bromo-*N*-[2-(1*H*-imidazol-4-yl)ethyl]pyrazine-2-carboxamide. Purification by preparative HPLC 30 (colonn: C18, 19x100 mm, eluent: water+0.1% TFA/acetonitrile, 50/20 to 50/50) followed by treatment of the base (in methanol) with HCl (1 M in diethyl ether). The formed precipitate was filtered off and dried in vacuo to give the title compound as a yellow solid.

Yield: 4%: ^1H NMR (DMSO- d_6 , 400 MHz) δ 8.96 (m, 1 H), 8.42 (d, $J = 8$ Hz, 2 H), 7.87 (d, $J = 8$ Hz, 2 H), 7.68 (br s, 2 H), 6.97 (br s, 1 H), 3.56 (m, 2 H), 3.18 (m, 4 H), 2.81 (m, 2 H), 1.66 (m, 4 H); MS (ES) m/z 442 ($M^+ + 1$).

5 **Example 15**

3-Amino-*N*-[3-(1*H*-imidazol-1-yl)propyl]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide hydrochloride

The title compound was prepared as described for Example 13 using 3-amino-6-bromo-*N*-[3-(1*H*-imidazol-1-yl)propyl]pyrazine-2-carboxamide. Purification by column
10 chromatography on silica using methylene chloride/methanol/triethyl amine, (95:5:0.1), gave the free base that was subsequently dissolved in methanol and treated with HCl (1 M in diethyl ether). Additional diethyl ether was added, the formed precipitate was filtered off and dried under vacuo to give the title compound as a yellow solid. Yield: 18%: ^1H NMR (DMSO- d_6 , 400 MHz) δ 9.21 (s, 1 H), 9.06 (m, 1 H), 8.96 (s, 1 H), 8.43 (d, $J = 8$ Hz, 2 H),
15 7.85 (m, 3 H), 7.70 (s, 1 H), 4.27 (t, $J = 7$ Hz, 2 H), 3.36 (q, $J = 7$ Hz, 2 H), 3.17 (m, 4 H), 2.14 (quin, $J = 7$ Hz, 2 H), 1.65 (m, 4 H); MS (ES) m/z 456 ($M^+ + 1$).

Example 16

20 **3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-(2-thien-2-ylethyl)pyrazine-2-carboxamide hydrochloride**

Triisopropyl borate (0.82 mL, 3.6 mmol) was added to a stirred solution of 1-[(4-bromophenyl)sulfonyl]-4-methylpiperazine (0.38 g, 1.2 mmol; described: in Keasling, H. H. et al. *J. Med. Chem.* **1965**, 8, 548-550) in anhydrous tetrahydrofuran (15 mL) at -78°C under an atmosphere of nitrogen, followed by dropwise addition of *n*-butyllithium (2.4 mL,
25 3.6 mmol) over 10 min. The resulting mixture was allowed to warm up to room temperature and was stirred for another 10 min at ambient temperature. Aqueous HCl (3 M, 1.9 mL, 6.0 mmol) was added and the mixture was stirred for 10 min, followed by an addition of sodium carbonate (1.26 g, 11.9 mmol). 3-Amino-6-bromo-*N*-(2-thien-2-ylethyl)pyrazine-2-carboxamide (0.272 g, 0.83 mmol) and Pd(dppf) Cl_2 (39 mg, 0.05
30 mmol) were added and the resulting mixture was heated at 65°C for 1 h. The solvent was evaporated, the resulting residue dissolved in methylene chloride/water, and the aqueous phase was extracted with ethyl acetate. The combined organic phases were evaporated,

methanol was added, and the insoluble material was filtered off. The solvent was evaporated and the residue was purified on a silica gel column using methylene chloride/methanol /triethyl amine, (98:2:0.1), as the eluent. The crude product was purified by re-crystallization from methanol to give the free base that was treated with HCl (1.0 M in diethyl ether, 0.6 mmol). The formed precipitate was filtered off and dried under vacuo to give 25 mg (6% yield) of the title compound as a yellow solid: ^1H NMR (DMSO- d_6 , 400 MHz) δ 10.55 (br s, 1 H), 9.05 (m, 1 H), 8.99 (s, 1 H), 8.46 (d, J = 8 Hz, 2 H), 7.82 (d, J = 8 Hz, 2 H), 7.37 (d, J = 5 Hz, 1 H), 6.98 (m, 2 H), 3.83 (m, 2 H), 3.58 (m, 2 H), 3.46 (m, 2 H), 3.13 (m, 4 H), 2.75 (s, 3 H), 2.67 (m, 2 H); MS (ES) m/z 487 (M^+ +1).

Example 17

3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-(thien-2-ylmethyl)pyrazine-2-carboxamide hydrochloride

The title compound was prepared as described for Example 16 using 3-amino-6-bromo-*N*-(thien-2-ylmethyl)pyrazine-2-carboxamide. Yield: 46%: ^1H NMR (DMSO- d_6 , 400 MHz) δ 10.9 (br s, 1 H), 9.56 (t, J = 6 Hz, 1 H), 8.99 (s, 1 H), 8.48 (d, J = 8 Hz, 2 H), 7.81 (d, J = 8 Hz, 2 H), 7.38 (d, J = 4 Hz, 1 H), 7.05 (s, 1 H), 6.97 (dd, J = 5, 4 Hz, 1 H), 4.68 (d, J = 6 Hz, 2 H), 3.81 (d, J = 12 Hz, 2 H), 3.44 (d, J = 12 Hz, 2 H), 3.15 (m, 4 H), 2.72 (s, 3 H); MS (ES) m/z 473 (M^+ +1).

Example 18

3-Amino-*N*-(2-methoxyethyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride

The title compound was prepared as described for Example 16 using 3-amino-6-bromo-*N*-(2-methoxyethyl)pyrazine-2-carboxamide. Yield: 44%: ^1H NMR (DMSO- d_6 , 400 MHz) δ 11.0 (br s, 1 H), 8.98 (s, 1 H), 8.92 (s, 1 H), 8.46 (d, J = 8 Hz, 2 H), 7.82 (d, J = 8 Hz, 2 H), 3.82 (d, J = 13 Hz, 2 H), 3.50 (s, 3 H), 3.45 (d, J = 13 Hz, 2 H), 3.28 (s, 3 H), 3.15 (m, 2 H), 2.72 (m, 6 H); MS (ES) m/z 435 (M^+ +1).

Example 19

3-Amino-*N*-(3-methoxypropyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride

Triisopropyl borate (0.82 mL, 3.6 mmol) was added to a stirred solution of 1-[(4-bromophenyl)sulfonyl]-4-methylpiperazine (0.380 g, 1.2 mmol; described: in Keasling, H. H. et al. *J. Med. Chem.* **1965**, 8, 548-550) in anhydrous tetrahydrofuran (15 mL) at -78 °C under an atmosphere of nitrogen, followed by dropwise addition of n-butyllithium (2.4 mL, 3.6 mmol) over 10 min. The resulting mixture was allowed to warm up to room temperature and was stirred for another 10 min at ambient temperature. HCl (3 M, 1.9 mL, 6.0 mmol) was added and the mixture was stirred for another 10 min, followed by an addition of sodium carbonate (1.26 g, 11.9 mmol). After 30 min, 3-amino-6-bromo-*N*-(3-methoxypropyl)pyrazine-2-carboxamide (0.24 g, 0.83 mmol) and Pd(dppf)Cl₂ (39 mg, 0.05 mmol) were added and the resulting mixture was heated at 65 °C for 22 h. The reaction mixture was evaporated and the residue was dissolved in NaHCO₃ (aq. sat.)/ethyl acetate, the aqueous phase was extracted with ethyl acetate and the combined organic phases were evaporated. The crude product was purified on a silica gel column using methylene chloride/methanol/triethyl amine, (9:1:0.1), as the solvent. The product was eluted from the silica with methanol and the solvent was evaporated to give the free base. The base was dissolved in methanol (10 mL) and the mixture was treated with HCl (1.0 M in diethyl ether, 1 mL) followed by addition of diethyl ether (5 mL). The formed precipitate was filtered off and dried at 40 °C in vacuo to give 70 mg (19% yield) of the title compound as a yellow solid: ¹H NMR (DMSO-d₆, 400 MHz) δ 11.02 (br s, 1 H), 8.97 (s, 2 H), 8.46 (d, *J* = 9 Hz, 2 H), 7.82 (d, *J* = 9 Hz, 2 H), 3.82 (d, *J* = 13 Hz, 2 H), 3.41 (m, 6 H), 3.27 (s, 3 H), 3.15 (m, 2 H), 2.72 (m, 5 H), 1.81 (m, 2 H); MS (ES) *m/z* 449 (M⁺+1).

Example 20

3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]pyrazine-2-carboxamide hydrochloride

The title compound was prepared as described for Example 19 using 3-amino-6-bromo-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]pyrazine-2-carboxamide. Yield: 22%: ¹H NMR (DMSO-d₆, 400 MHz) δ; 11.12 (br s, 1 H), 9.07 (t, *J* = 6 Hz, 1 H), 9.00 (s, 1 H), 8.52 (d, *J* = 8 Hz, 2 H), 7.80 (d, *J* = 8 Hz, 2 H), 3.82 (d, *J* = 12 Hz, 2 H), 3.40 (m, 4 H), 3.27 (m, 4 H), 3.16 (m, 2 H), 2.73 (m, 5 H), 2.25 (t, *J* = 8 Hz, 2 H), 1.93 (t, *J* = 7 Hz, 2 H), 1.72 (t, *J* = 7 Hz, 2 H); MS (ES) *m/z* 502 (M⁺+1).

Example 21**3-Amino-*N*-(cyanomethyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide dihydrochloride**

The title compound was prepared as described for Example 19 using 3-amino-6-bromo-*N*-(cyanomethyl)pyrazine-2-carboxamide. Yield: 19%; ^1H NMR (DMSO- d_6 , 400 MHz) δ 10.49 (br s, 1 H), 9.50 (t, $J = 6$ Hz, 1 H), 9.05 (s, 1 H), 8.49 (d, $J = 8$ Hz, 2 H), 7.84 (m, 1 H), 7.83 (d, $J = 8$ Hz, 2 H), 4.36 (d, $J = 6$ Hz, 2 H), 3.83 (d, $J = 12$ Hz, 2 H), 3.36 (m, 2 H), 3.16 (m, 2 H), 2.74 (s, 3 H), 2.66 (m, 2 H); MS (ES) m/z 416 ($M^+ + 1$).

Example 22**3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[2-(1*H*-pyrrol-1-yl)ethyl]-2-pyrazinecarboxamide hydrochloride**

Triethyl amine (0.57 mL, 4.13 mmol) was added to a mixture of 3-amino-6-bromo-2-pyrazinecarboxylic acid (0.30 g, 1.38 mmol; described in: Ellingson, R. C.; Henry, R. L. *J. Am. Chem. Soc.* **1949**, 2798-2800), O-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluroniumtetrafluoroborate (0.486 g, 1.51 mmol) and 1-hydroxybenzotriazole (0.204 g, 1.51 mmol) in *N,N*-dimethylformamide/acetonitrile, (1:1, 5 mL). After stirring for 0.5 h at room temperature, 2-(1*H*-pyrrol-1-yl)-1-ethanamine (0.182 g, 1.65 mmol) was added and the resulting mixture was stirred overnight at room temperature. Approximately, 10 mL water was added and a precipitation was formed. The precipitation was filtered and washed with water which gave 0.21 g (50% yield) of a light brown solid: MS (ESP) m/z 310, 312 ($M^+ + 1$).

The solid (0.16 g, 0.516 mmol) from previous step was dissolved in tetrahydrofuran/water (5:1, 5 mL) together with [4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]boronic acid (0.220 g, 0.77 mmol), sodium carbonate (0.164 g, 1.55 mmol) and Pd(dppf)Cl₂ (0.013 g, 1.5 nmol). The resulting mixture was stirred at 70 °C overnight (N₂-atmosphere). The mixture was evaporated onto silica and purified on silica using toluene/acetonitrile, (1:2 to 1:4), as the eluent which afforded a yellow solid which was dried in vacuo at 40 °C. The product was dissolved in a methylene chloride/methanol mixture, (9:1), and hydrochloride acid in diethyl ether (0.28 mL, 1 M) was added. The precipitate was washed with diethyl ether and dried in vacuo to give 69 mg (23% yield) of the title compound: ^1H NMR (DMSO- d_6) δ 8.94 (s, 1 H), 8.90 (t, $J = 6$ Hz, 1 H), 8.43 (d, $J = 8$ Hz, 2 H), 7.82 (d, $J = 8$

Hz, 2 H), 6.79 (t, $J = 2$ Hz, 2 H), 6.01 (t, $J = 2$ Hz, 2 H), 4.12 (t, $J = 7$ Hz, 2 H), 3.83 (d, $J = 12$ Hz, 2 H), 3.63 (quart, $J = 6$ Hz, 2 H), 3.44 (d, $J = 12$ Hz, 2 H), 3.15 (m, 2 H), 2.73 (m, 5 H); ^{13}C NMR (DMSO- d_6) δ 165.8, 154.5, 144.8, 140.8, 135.9, 133.3, 127.9, 126.1, 124.6, 120.7, 107.8, 51.5, 47.6, 43.0, 41.8; MS (ESP) m/z 470 ($M^+ + 1$).

5

The following Examples, 23 – 26, were synthesized as described for Example 22.

Example 23

10 **3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[2-(methylsulfonyl)ethyl]-2-pyrazinecarboxamide hydrochloride**

Starting material: 2-aminoethylmethylsulfone hydrochloride. The title compound was purified by chromatography on silica gel using a gradient toluene/acetonitrile, (1:0 to 1:2), as the eluent, followed by formation of the hydrochloric salt. Yield: 18%; ^1H NMR (D_2O) δ 8.43 (s, 1 H), 7.89 (d, $J = 8$ Hz, 2 H), 7.74 (d, $J = 8$ Hz, 2 H), 3.97 (d, $J = 14$ Hz, 2 H), 3.89 (t, $J = 6$ Hz, 2 H), 3.63 (m, 4 H), 3.29 (m, 2 H), 3.25 (s, 3 H), 2.94 (s, 3 H), 2.88 (t, $J = 12$ Hz, 2 H); ^{13}C NMR (D_2O) δ 166.3, 163.3, 143.4, 133.5, 128.4, 125.9, 53.1, 53.0, 43.5, 43.1, 10.9, 33.0; MS (ESP) m/z 483 ($M^+ + 1$).

Example 24

20 **N-[2-(Acetylamino)ethyl]-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride**

Starting material: *N*-acetylethylendiamine. The title compound was purified by chromatography on silica gel using a gradient toluene/acetonitrile, (1:0 to 0:1), as the eluent, followed by formation of the hydrochloric salt. Yield: 25%; ^1H NMR (D_2O) δ 8.42 (s, 1 H), 7.93 (d, $J = 8$ Hz, 2 H), 7.74 (d, $J = 8$ Hz, 2 H), 3.96 (d, $J = 13$ Hz, 2 H), 3.64 (d, $J = 13$ Hz, 2 H), 3.43 (m, 4 H), 3.28 (m, 2 H), 2.93 (s, 3 H), 2.87 (s, 2 H), 2.02 (s, 3 H); ^{13}C NMR (D_2O) δ 174.6, 166.1, 152.2, 141.1, 139.9, 136.6, 133.3, 128.2, 125.8, 52.7, 43.3, 42.9, 39.1, 38.7, 22.1; MS (ESP) m/z 462 ($M^+ + 1$).

30 Example 25

3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]-2-pyrazinecarboxamide hydrochloride

Starting material: 1-(2-aminoethyl)imidazolidin-2-one trifluoroacetic acid (McKay, A.F., Paris, G.Y., Kreling, M.-E. *J. Amer. Chem. Soc.* **1957**, 79, 5276). The title compound was purified by chromatography on silica gel using a gradient chloroform/methanol, (98:2 to 4:1), as the eluent, followed by formation of the hydrochloric salt. Yield: 4%: ¹H NMR (D₂O) δ 8.56 (s, 1 H), 8.06 (d, *J* = 8 Hz, 2 H), 7.83 (d, *J* = 8 Hz, 2 H), 3.98 (d, *J* = 14 Hz, 2 H), 3.65 (m, 4 H), 3.57 (t, *J* = 5 Hz, 2 H), 3.45 (m, 4 H), 3.28 (m, 2 H), 2.93 (s, 3 H), 2.86 (m, 2 H); MS (ESP) *m/z* 489 (M⁺+1).

Example 26

10 3-Amino-N-[2-(aminosulfonyl)ethyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride

Starting material: 2-aminoethanesulfonic acid amide hydrochloride. The final compound was purified by chromatography on silica gel using a gradient toluene/acetonitrile, (1:0 to 0:1), as the eluent followed by formation of the hydrochloric salt. Yield: 21% of the title compound as a yellow solid: ¹H NMR (DMSO-*d*₆) δ 9.13 (t, *J* = 6 Hz, 1 H), 8.99 (s, 1 H), 8.42 (d, *J* = 8 Hz, 2 H), 7.77 (d, *J* = 8 Hz, 2 H), 7.03 (s, 2 H), 3.74 (quart, *J* = 6 Hz, 2 H), 3.28 (m, 2 H), 2.95 (br s, 4 H), 2.45 (br s, 4 H), 2.20 (br s, 3 H); MS (ESP) *m/z* 484(M⁺+1).

Example 27

20 Methyl 3-amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate

4-(Pyrrolidin-1-ylsulfonyl)phenylboronic acid (0.33 g, 1.29 mmol), methyl 3-amino-6-bromopyrazine-2-carboxylate (0.25 g, 1.08 mmol; described in: H. Ellingson, *J. Amer. Chem. Soc.* **1949**, 2798), K₃PO₃ (3 M, 1.1 mL, 3.2 mmol), and Pd(dppf)Cl₂ (0.044 g, 54 μmol) were suspended in ethylene glycol dimethyl ether/water (1.5:0.5 mL) and heated in a microwave oven at 160 °C for 10 min. The reaction was repeated 3 times. The combined product mixtures were evaporated with silica gel and the crude product was purified by chromatography on silica gel using a heptan/ethylacetate gradient as the eluent to give 0.96 g (82% yield) of the title compound: MS (ES) *m/z* 363 (M⁺+1).

30 Example 28

Methyl 3-[[2,6-dimethoxy-4-(2-phenylethoxy)benzyl]amino]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate polystyrene

Sodiumtriacetoxo borohydride (2.6 g, 12.2 mmol) in *N,N*-dimethylformamide/acetic acid, (98:2, 20 mL), and trimethylsilyl chloride (1.17 mL, 9.18 mmol) was added to a mixture of methyl 3-amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate (4.4 g, 12.2 mmol) and 2-(3,5-dimethoxy-4-formylphenoxy) ethyl polystyrene (12 g, 0.51 mmol/g) in *N,N*-dimethylformamide (60 mL). The mixture was shaken for 3 h and then filtered. The polystyrene resin was washed, three times, with *N,N*-dimethylformamide and three times with methylene chloride. The procedure was repeated using sodiumtriacetoxo borohydride (2.6 g, 12.24 mmol) in *N,N*-dimethylformamide/acetic acid (98:2, 20 mL), trimethylsilyl chloride (1.17 ml, 9.18 mmol) and methyl 3-amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate (12 g, 0.51 mmol/g) and shaking was continued for 18 h. The polystyrene resin was washed, three times, with *N,N*-dimethylformamide, three times with methylene chloride and three times with methanol. The resin was dried under vacuum to give 12.5 g of the title compound.

Analysis: The title compound (50 mg) was treated with trifluoroacetic acid in methylene chloride (conc. 95%) for 30 min, filtered and the solvent was analyzed by MS: MS (ESI) 363 m/z ($M^+ + 1$) (which corresponds to the starting material).

Example 29

3-[[2,6-Dimethoxy-4-(2-phenylethoxy)benzyl]amino]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylic acid polystyrene

An aqueous solution of lithium hydroxide (4 M, 10 mL) was added to a suspension of methyl 3-[[2,6-dimethoxy-4-(2-phenylethoxy)benzyl]amino]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate polystyrene (12 g, 0.51 mmol/g) in tetrahydrofuran (100 mL). The mixture was shaken for 17 h. Filtering and washing of the resin three times with *N,N*-dimethylformamide/water, (4:1), and three times with *N,N*-dimethylformamide/acetic acid, (98:2), and three times with methanol and drying of the resin gave 11.8 g of the title compound.

Analysis: The title compound (50 mg) was treated with trifluoroacetic acid in methylene chloride (conc. 95%) for 30 min, filtered and the solvent was analyzed by MS: MS (ESI) 349 m/z ($M^+ + 1$).

Example 30**3-Amino-*N*-(2-cyanoethyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide**

3-Aminopropanenitrile (36 mg, 0.51 mmol), O-(benzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium tetrafluoroborate (0.164 g, 0.51 mmol) and 1-hydroxybenzotriazole hydrate (69 mg, 0.51 mmol) was added to 3-{[2,6-dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylic acid polystyrene (0.50 g, 0.51 mmol/g, 0.255 mmol) in *N,N*-dimethylformamide (2 mL). The mixture was shaken for 5 min where after diisopropylethyl amine (0.133 mL, 0.765 mmol) was added. The mixture was shaken for 18 h, filtered and washed with *N,N*-dimethylformamide and three times with methylene chloride. The product was isolated by treating the resin with trifluoroacetic acid in methylene chloride (conc. 95%) for 30 min and then filtered. The solution was evaporated and purification by preparative HPLC (column: XTerra C8 19x300 mm, eluent: gradient acetonitrile/water, (20:80 to 80:20)), gave 1 mg (1% yield) of the title compound: ¹H NMR (CDCl₃, 400 MHz) δ 8.70 (s, 1 H), 8.01 (d, *J* = 8 Hz, 2 H), 7.93 (d, *J* = 8 Hz, 2 H), 3.79 (m, 2 H), 3.30 (m, 4 H), 2.79 (t, *J* = 6 Hz, 2 H), 1.80 (m, 4 H); MS (ESI) 401 *m/z* (M⁺+1).

The following Examples, 31 – 35, were synthesized as described for Example 30.

Example 31**3-Amino-*N*-(3-amino-3-oxopropyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide**

Starting material: β-alaninamide. Yield: 2 %: ¹H NMR (CDCl₃, 400 MHz) δ 8.60 (s, 1 H), 8.03 (d, *J* = 8 Hz, 2 H), 7.85 (d, *J* = 8 Hz, 2 H), 3.64 (t, *J* = 6 Hz, 2 H), 3.20 (m, 4 H), 2.50 (t, *J* = 6 Hz, 2 H), 1.72 (m, 4 H); MS (ESI) 419 *m/z* (M⁺+1).

Example 32**3-Amino-*N*-(2-nitrobenzyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide**

Starting material: 1-(2-nitrophenyl)methanamine. Yield: 1.8%: ¹H NMR (CDCl₃, 400 MHz) δ 8.80 (s, H), 8.70 (s, H), 8.12 (d, *J* = 7 Hz, 1 H), 8.04 (d, *J* = 8 Hz, 2 H), 7.90 (d, *J*

= 8 Hz, 2 H), 7.73 (dd, $J = 8$ Hz, 1 H), 7.50 (m, 1 H), 7.66 (m, 1 H), 4.94 (d, $J = 7$ Hz, 2 H), 3.30 (m, 4 H), 1.8 (m, 4 H); MS (ESI) 483 m/z ($M^+ + 1$).

Example 33

5 **3-Amino-*N*-(2-methoxybenzyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide**

Starting material: 1-(2-methoxyphenyl)methanamine. Yield: 1.6%: ^1H NMR (CDCl_3 , 400 MHz) δ 8.64 (s, 1 H), 8.01 (d, $J = 8$ Hz, 2 H), 7.89 (d, $J = 8$ Hz, 2 H), 7.31 (d, $J = 7$ Hz, 2 H), 6.94 (m, 2 H), 4.68 (d, $J = 6$ Hz, 2 H), 3.94 (m, 3 H), 3.41 (m, 1 H), 3.27 (m, 4 H), 1.8 (m, 4 H); MS (ESI) 468 m/z ($M^+ + 1$).

Example 34

15 **3-Amino-*N*-(3-morpholin-4-ylpropyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide**

Starting material: 3-morpholin-4-ylpropan-1-amine. Yield: 1.4%: ^1H NMR (CDCl_3 , 400 MHz) δ 8.67 (s, 1 H), 8.02 (d, $J = 8$ Hz, 2 H), 7.94 (d, $J = 8$ Hz, 2 H), 3.66 (t, $J = 5$ Hz, 4 H), 3.58 (m, 2 H), 3.30 (m, 4 H), 2.49 (t, $J = 7$ Hz, 2 H), 2.48 (m, 4 H), 1.85 (t, $J = 7$ Hz, 2 H), 1.79 (m, 4 H); MS (ESI) 475 m/z ($M^+ + 1$).

20 **Example 35**

3-Amino-*N*-[3-(4-methylpiperazin-1-yl)propyl]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide

Starting material: 3-(4-methylpiperazin-1-yl)propan-1-amine. Yield: 3.8%:
 ^1H NMR (CD_3OD , 400 MHz) δ 8.77 (s, 1 H), 8.24 (d, $J = 8$ Hz, 2 H), 7.05 (d, $J = 8$ Hz, 2 H), 3.54 (t, $J = 7$ Hz, 2 H), 3.36 (m, 4 H), 3.32 (m, 4 H), 2.56 (d, $J = 7$ Hz, 4 H), 2.28 (s, 3 H), 2.09 (s, 1 H), 1.90 (m, 2 H), 1.84 (m, 4 H); MS (ESI) 488 m/z ($M^+ + 1$).

Pharmaceutical compositions

30 According to one aspect of the present invention there is provided a pharmaceutical composition comprising a compound of formula I, as a free base or a pharmaceutically

acceptable salt, solvate or solvate of salt thereof, for use in the prevention and/or treatment of conditions associated with glycogen synthase kinase-3.

The composition may be in a form suitable for oral administration, for example as a tablet,
5 for parenteral injection as a sterile solution or suspension. In general the above compositions may be prepared in a conventional manner using pharmaceutically carriers or diluents. Suitable daily doses of the compounds of formula I in the treatment of a mammal, including man, are approximately 0.01 to 250 mg/kg bodyweight at peroral administration and about 0.001 to 250 mg/kg bodyweight at parenteral administration. The typical daily
10 dose of the active ingredients varies within a wide range and will depend on various factors such as the relevant indication, the route of administration, the age, weight and sex of the patient and may be determined by a physician.

A compound of formula I, or a pharmaceutically acceptable salt, solvate or solvate of salt
15 thereof, can be used on its own but will usually be administered in the form of a pharmaceutical composition in which the formula I compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable diluent or carrier. Dependent on the mode of administration, the pharmaceutical composition may comprise from 0.05 to 99 %w (per cent by weight), for example from 0.10 to 50 %w, of active
20 ingredient, all percentages by weight being based on total composition.

A diluent or carrier includes water, aqueous polyethylene glycol, magnesium carbonate, magnesium stearate, talc, a sugar (such as lactose), pectin, dextrin, starch, tragacanth, microcrystalline cellulose, methyl cellulose, sodium carboxymethyl cellulose or cocoa
25 butter.

A composition of the invention can be in tablet or injectable form. The tablet may additionally comprise a disintegrant and/or may be coated (for example with an enteric coating or coated with a coating agent such as hydroxypropyl methylcellulose).

30

The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula I, or a

pharmaceutically acceptable salt, solvate or solvate of salt thereof, a hereinbefore defined, with a pharmaceutically acceptable diluent or carrier.

- An example of a pharmaceutical composition of the invention is an injectable solution
- 5 containing a compound of the invention, or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, as hereinbefore defined, and sterile water, and, if necessary, either sodium hydroxide or hydrochloric acid to bring the pH of the final composition to about pH 5, and optionally a surfactant to aid dissolution.
- 10 Liquid solution comprising a compound of formula I, as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof, dissolved in water.

<u>Solution</u>	<u>mg/mL</u>
Compound X	5.0% w/v
Pure water	To 100%

15 **Medical use**

Surprisingly, it has been found that the compounds defined in the present invention, as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, are well suited for inhibiting glycogen synthase kinase-3 (GSK3). Accordingly, the compounds of the present invention are expected to be useful in the prevention and/or treatment of

20 conditions associated with glycogen synthase kinase-3 activity, i.e. the compounds may be used to produce an inhibitory effect of GSK3 in mammals, including man, in need of such prevention and/or treatment.

GSK3 is highly expressed in the central and peripheral nervous system and in other tissues. Thus, it is expected that compounds of the invention are well suited for the prevention

25 and/or treatment of conditions associated with glycogen synthase kinase-3 in the central and peripheral nervous system. In particular, the compounds of the invention are expected to be suitable for prevention and/or treatment of conditions associated with especially, dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia

Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica.

Other conditions are selected from the group consisting of amyotrophic lateral sclerosis,
5 corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss and contraceptive medication, Type I and Type II diabetes, diabetic neuropathy and diabetes
10 related disorders.

Further conditions are selected from the group consisting predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive
15 decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies and androgenetic alopecia.

One embodiment of the invention relates to the prevention and/or treatment of dementia and Alzheimer's Disease.

20

Another embodiment of the invention relates to the prevention and/or treatment of Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders.

The dose required for the therapeutic or preventive treatment of a particular disease
25 will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated.

The present invention relates also to the use of a compound of formula I as defined hereinbefore, in the manufacture of a medicament for the prevention and/or treatment of
30 conditions associated with glycogen synthase kinase-3.

In the context of the present specification, the term "therapy" also includes "prevention" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

- 5 The invention also provides for a method of treatment and/or prevention of conditions associated with glycogen synthase kinase-3 comprising administering to a mammal, including man in need of such treatment and/or prevention a therapeutically effective amount of a compound of formula I, as hereinbefore defined.

Non-medical use

- 10 In addition to their use in therapeutic medicine, the compounds of formula I as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof, are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effects of inhibitors of GSK3 related activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new
15 therapeutics agents.

Pharmacology

Determination of ATP competition in Scintillation Proximity GSK3 β Assay.

GSK3 β scintillation proximity assay.

- 20 The competition experiments were carried out in duplicate with 10 different concentrations of the inhibitors in clear-bottom microtiter plates (Wallac, Finland). A biotinylated peptide substrate, Biotin-Ala-Ala-Glu-Glu-Leu-Asp-Ser-Arg-Ala-Gly-Ser(PO₃H₂)-Pro-Gln-Leu (AstraZeneca, Lund), was added at a final concentration of 1 μ M in an assay buffer containing 1 mU recombinant human GSK3 β (Dundee University, UK), 12 mM
25 morpholinepropanesulfonic acid (MOPS), pH 7.0, 0.3 mM EDTA, 0.01% β -mercaptoethanol, 0.004 % Brij 35 (a natural detergent), 0.5 % glycerol and 0.5 μ g BSA/25 μ l. The reaction was initiated by the addition of 0.04 μ Ci [γ -³³P]ATP (Amersham, UK) and unlabelled ATP at a final concentration of 1 μ M and assay volume of 25 μ l. After
incubation for 20 minutes at room temperature, each reaction was terminated by the
30 addition of 25 μ l stop solution containing 5 mM EDTA, 50 μ M ATP, 0.1 % Triton X-100 and 0.25 mg streptavidin coated Scintillation Proximity Assay (SPA) beads (Amersham,

UK). After 6 hours the radioactivity was determined in a liquid scintillation counter (1450 MicroBeta Trilux, Wallac). The inhibition curves were analysed by non-linear regression using GraphPad Prism, USA. The K_m value of ATP for GSK3 β , used to calculate the inhibition constants (K_i) of the various compounds, was 20 μ M.

5

The following abbreviations have been used:

MOPS Morpholinepropanesulfonic acid

EDTA Ethylenediaminetetraacetic acid

BSA Bovin Serum Albumin

10 ATP Adenosine Triphosphate

SPA Scintillation Proximity Assay


GSK3 Glycogen synthase kinase 3

Results

Typical K_i values for the compounds of the present invention are in the range of about
15 0.001 to about 10,000 nM. Other values for K_i are in the range of about 0.001 to about
1000 nM. Further values for K_i are in the range of about 0.001 nM to about 300 nM.

CLAIMS

1. A compound having the formula I



wherein:

Z is N;

Y is CONR⁵, NR⁵CO, SO₂NR⁵, NR⁵SO₂, CH₂NR⁵, NR⁵CONR⁵, CH₂CO, CO or CH₂O;

10 X is CH or N;

P is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected from N, O or S and said phenyl ring or 5 or 6 membered heteroaromatic ring may optionally be fused with a 5 or 6 membered saturated, partially saturated or unsaturated ring containing atoms independently selected from C, N, O or S;

15 Q is C₁₋₆alkyl, C₂₋₆alkenyl or C₂₋₆alkynyl;

R is CHO, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C₀₋₆alkyl(SO₂)NR¹R², OC₀₋₆alkyl(SO₂)NR¹R², OC₁₋₆alkyl(SO)NR¹R², C₁₋₆alkyl(SO)NR¹R², C₀₋₆alkylNR¹(SO)R², OC₁₋₆alkylNR¹(SO)R², C₀₋₆alkylNR¹(SO₂)NR¹R², OC₁₋₆alkylNR¹(SO₂)R², C₀₋₆alkyl(SO₂)C₁₋₆alkylNR¹R², OC₀₋₆alkyl(SO₂)C₁₋₆alkylNR¹R²,

20 C₀₋₆alkyl(SO)C₁₋₆alkylNR¹R², OC₁₋₆alkyl(SO)C₁₋₆alkylNR¹R², C₀₋₆alkylSC₁₋₆alkylNR¹R², OC₁₋₆alkylSC₁₋₆alkylNR¹R², OC₁₋₆alkylOC₁₋₆alkyl, C₁₋₆alkylOC₁₋₆alkylNR¹R², OC₁₋₆alkylOC₁₋₆alkylNR¹R², C₀₋₆alkylCONR¹⁰R¹¹, OC₀₋₆alkylCONR¹R², OC₁₋₆alkylNR¹R², C₀₋₆alkylNR¹⁰(CO)R¹¹, OC₁₋₆alkylNR¹(CO)R², C₀₋₆alkylNR¹¹(CO)R¹⁰, C₀₋₆alkylCOR¹¹, OC₁₋₆alkylCOR¹, C₀₋₆alkylNR¹⁰R¹¹, C₀₋₆alkylO(CO)R¹¹, OC₁₋₆alkylO(CO)R¹, C₀₋₆alkylC(NR¹⁰)NR¹⁰R¹¹, C₀₋₆alkylC(NR¹¹)N(R¹⁰)₂, OC₀₋₆alkylC(NR¹)NR¹R², C₀₋₆alkylNR¹⁰(CO)OR¹¹, OC₁₋₆alkylNR¹(CO)OR²,

$C_{0-6}alkylNR^{11}(CO)OR^{10}$, $OC_{1-6}alkylCN$, NR^1OR^2 , $C_{0-6}alkyl(CO)OR^8$, $OC_{1-6}alkyl(CO)OR^1$, $NR^1(CO)NR^1R^2$, $NR^1(CO)(CO)R^2$, $NR^1(CO)(CO)NR^1R^2$, OR^{12} or SO_3R^1 ;

R^1 and R^2 are independently selected from hydrogen, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{0-6}alkylC_{3-6}cycloalkyl$, $C_{0-6}alkylheterocycloalkyl$, $C_{1-6}alkylNR^6R^7$,

- 5 $C_{0-6}alkylaryl$ and $C_{0-6}alkylheteroaryl$, wherein any $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{0-6}alkylC_{3-6}cycloalkyl$, $C_{0-6}alkylheterocycloalkyl$, $C_{0-6}alkylaryl$, $C_{0-6}alkylheteroaryl$ may be substituted by one or more A;

R^1 and R^2 may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring

- 10 may be optionally substituted by A;

R^3 is independently selected from halogen, nitro, CHO, $C_{0-6}alkylCN$, $OC_{1-6}alkylCN$, $C_{0-6}alkylOR^6$, $OC_{1-6}alkylOR^6$, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, $C_{0-6}alkylNR^6R^7$, $OC_{1-6}alkylNR^6R^7$, $OC_{1-6}alkylOC_{1-6}alkylNR^6R^7$, NR^6OR^7 , $C_{0-6}alkylCO_2R^6$, $OC_{1-6}alkylCO_2R^6$,

- 15 $C_{0-6}alkylCONR^6R^7$, $OC_{1-6}alkylCONR^6R^7$, $OC_{1-6}alkylNR^6(CO)R^7$, $C_{0-6}alkylNR^6(CO)R^7$, $O(CO)NR^6R^7$, $NR^6(CO)OR^7$, $NR^6(CO)NR^6R^7$, $O(CO)OR^6$, $O(CO)R^6$, $C_{0-6}alkylCOR^6$, $OC_{1-6}alkylCOR^6$, $NR^6(CO)(CO)R^6$, $NR^6(CO)(CO)NR^6R^7$, SR^6 , $C_{0-6}alkyl(SO_2)NR^6R^7$, $OC_{1-6}alkylNR^6(SO_2)R^7$, $OC_{0-6}alkyl(SO_2)NR^6R^7$, $C_{0-6}alkyl(SO)NR^6R^7$, $OC_{1-6}alkyl(SO)NR^6R^7$, SO_3R^6 , $C_{0-6}alkylNR^6(SO_2)NR^6R^7$, $C_{0-6}alkylNR^6(SO)R^7$,
20 $OC_{1-6}alkylNR^6(SO)R^7$, $OC_{0-6}alkylSO_2R^6$, $C_{0-6}alkylSO_2R^6$, $C_{0-6}alkylSOR^6$, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{0-6}alkylC_{3-6}cycloalkyl$, $C_{0-6}alkylaryl$ and $C_{0-6}alkylheteroaryl$, wherein any $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{0-6}alkylC_{3-6}cycloalkyl$, $C_{0-6}alkylaryl$ and $C_{0-6}alkylheteroaryl$ may be optionally substituted by one or more A;

R^4 is independently selected from halogen, nitro, CHO, CN, $OC_{1-6}alkylCN$, OR^6 ,

- 25 $OC_{1-6}alkylOR^6$, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, NR^6R^7 , $OC_{1-6}alkylNR^6R^7$, NR^6OR^7 , CO_2R^6 , $OC_{1-6}alkylCO_2R^6$, $CONR^6R^7$, $OC_{1-6}alkylCONR^6R^7$, $OC_{1-6}alkylNR^6(CO)R^7$, $NR^6(CO)R^7$, $O(CO)NR^6R^7$, $NR^6(CO)OR^7$, $NR^6(CO)NR^6R^7$, $O(CO)OR^6$, $O(CO)R^6$, COR^6 , $OC_{1-6}alkylCOR^6$, $NR^6(CO)(CO)R^6$, $NR^6(CO)(CO)NR^6R^7$, SR^6 , $(SO_2)NR^6R^7$,
30 $OC_{1-6}alkylNR^6(SO_2)R^7$, $OC_{0-6}alkyl(SO_2)NR^6R^7$, $(SO)NR^6R^7$, $OC_{1-6}alkyl(SO)NR^6R^7$, SO_3R^6 , $NR^6(SO_2)NR^6R^7$, $NR^6(SO)R^7$, $OC_{1-6}alkylNR^6(SO)R^7$, $OC_{0-6}alkylSO_2R^6$, SO_2R^6 , SOR^6 , $C_{3-6}cycloalkyl$, phenyl, a 5 or 6 membered heteroaromatic ring containing one or

- more heteroatoms independently selected from N, O, or S, or a 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O, or S which heterocyclic group may be saturated or unsaturated, and said phenyl ring or 5 or 6 membered heteroaromatic ring or 5 or 6 membered heterocyclic ring may optionally be
- 5 fused with a 5 or 6 membered saturated, partially saturated or unsaturated ring containing atoms independently selected from C, N, O or S wherein any C₃₋₆cycloalkyl, phenyl, 5 or 6 membered heteroaromatic ring with one or two heteroatoms selected independently from N, O, or S or a 5 or 6 membered heterocyclic containing one or two heteroatoms selected independently from N, O, or S; may be optionally be substituted by one or more A;
- 10 m is 0, 1, 2, 3 or 4;
n is 0, 1, 2, 3 or 4;
R⁵ is hydrogen or C₁₋₆alkyl
R⁶ and R⁷ are independently selected from hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl and C₁₋₆alkylNR⁸R⁹;
- 15 R⁶ and R⁷ may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A and wherein a CH₂ group may optionally be replaced by a CO group;
R⁸ and R⁹ are independently selected from hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl and C₀₋₆alkylheteroaryl;
- 20 R⁸ and R⁹ may together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which heterocyclic ring may be optionally substituted by A;
R¹⁰ is hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl or C₁₋₆alkylNR⁸R⁹;
- 25 R¹¹ is C₁₋₆alkylNR⁸R⁹;
R¹⁰ and R¹¹ may together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which heterocyclic ring may be optionally substituted by A;
- 30 R¹² is a 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A; wherein any C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl,

C₀₋₆alkylheterocycloalkyl, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl defined under R⁵ to R¹² may be substituted by one or more A;

A is halo, oxo (=O), nitro, CHO, CN, OR⁶, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C₀₋₆alkylNR⁶R⁷, OC₁₋₆alkylNR⁶R⁷, CO₂R⁸, CONR⁶R⁷, NR⁶(CO)R⁶, O(CO)R⁶, COR⁶, SR⁶, (SO₂)NR⁶R⁷, (SO)NR⁶R⁷, SO₃R⁶, SO₂R⁶ or SOR⁶;

as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

2. A compound according to claim 1, wherein Z and X is N; P is phenyl; R is

10 C₀₋₆alkyl(SO₂)NR¹R²; and m is 0.

3. A compound according to claim 2, wherein R¹ and R² in C₀₋₆alkyl(SO₂)NR¹R² together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S.

15

4. A compound according to claim 3, wherein said heterocyclic ring comprises one or more N heteroatoms and said heterocyclic ring is optionally substituted by A, preferably a C₁₋₆alkyl.

20 5. A compound according to any one of claims 1 to 4, wherein Y is CONR⁵; R⁵ is hydrogen; Q is C₁₋₆alkyl; R⁴ is selected from: phenyl, 5 or 6 membered heteroaromatic ring containing one or more heteroatoms independently selected from N, O, or S or a 5 or 6 membered heterocyclic ring containing one or two heteroatoms selected independently from N, O, or S which heterocyclic group may be saturated or unsaturated, CN, OR⁶, SO₂R⁶, NR⁶(CO)R⁷, (SO₂)NR⁶R⁷, and CONR⁶R⁷; and n is 1; said phenyl or 5 or 6 membered heterocyclic ring optionally substituted by A.

25

6. A compound according to claim 5, wherein A is selected from OR⁶, C₁₋₆alkyl, oxo (=O) and nitro; and R⁶ and/or R⁷ is selected from C₁₋₆alkyl and hydrogen.

30

7. A compound which is

3-Amino-*N*-(2-cyanoethyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;

3-Amino-*N*-(3-amino-3-oxopropyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-

5 carboxamide;

3-Amino-*N*-(2-nitrobenzyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide

3-Amino-*N*-(2-methoxybenzyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-
carboxamide;

3-Amino-*N*-(3-morpholin-4-ylpropyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-

10 carboxamide;

3-Amino-*N*-[3-(4-methylpiperazin-1-yl)propyl]-6-[4-(pyrrolidin-1-
ylsulfonyl)phenyl]pyrazine-2-carboxamide;

as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof;

15 3-Amino-*N*-(2-morpholin-4-ylethyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-
carboxamide hydrochloride;

3-Amino-*N*-[2-(1*H*-imidazol-4-yl)ethyl]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-
carboxamide hydrochloride;

3-Amino-*N*-[3-(1*H*-imidazol-1-yl)propyl]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-
20 carboxamide hydrochloride;

3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-(2-thien-2-ylethyl)pyrazine-2-
carboxamide hydrochloride;

3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-(thien-2-ylmethyl)pyrazine-2-
carboxamide hydrochloride;

25 3-Amino-*N*-(2-methoxyethyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-
carboxamide hydrochloride;

3-Amino-*N*-(3-methoxypropyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-
2-carboxamide hydrochloride;

3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-[3-(2-oxopyrrolidin-1-
30 yl)propyl]pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-(cyanomethyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-
carboxamide dihydrochloride;

3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[2-(1*H*-pyrrol-1-yl)ethyl]-2-pyrazinecarboxamide hydrochloride;

3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[2-(methylsulfonyl)ethyl]-2-pyrazinecarboxamide hydrochloride;

5 *N*-[2-(Acetylamino)ethyl]-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;

3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[2-(2-oxo-1-imidazolidinyl)ethyl]-2-pyrazinecarboxamide hydrochloride;

3-Amino-*N*-[2-(aminosulfonyl)ethyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;

10 or as a free base or an alternative pharmaceutically acceptable salt, solvate or solvate of a salt thereof;

8. A pharmaceutical formulation comprising as active ingredient a therapeutically effective
15 amount of the compound according to any one of claims 1 to 7 in association with pharmaceutically acceptable carriers or diluents.

9. The pharmaceutical formulation according to claim 8 for use in the prevention and/or treatment of conditions associated with glycogen synthase kinase-3.

20

10. A compound as defined in any one of claims 1 to 7 for use in therapy.

11. Use of a compound according to any one of claims 1 to 7 in the manufacture of a medicament for prevention and/or treatment of conditions associated with glycogen
25 synthase kinase-3.

12. Use of a compound according to any one of claims 1 to 7 in the manufacture of a medicament for prevention and/or treatment of dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia
30 complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica.

13. The use according to claim 12 wherein the prevention and/or treatment is for Alzheimer's Disease.

14. Use of a compound according to any one of claims 1 to 7 in the manufacture of a
5 medicament for prevention and/or treatment of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss and contraceptive medication,
10 Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders.

15. Use of a compound according to claim 14, wherein the prevention and/or treatment is Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders.

16. Use of a compound according to any one of claims 1 to 7 in the manufacture of a
15 medicament for prevention and/or treatment of predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular
20 dementia, dementia with Lewy bodies, Frontotemporal dementia and androgenetic alopecia.

17. A method of prevention and/or treatment of conditions associated with glycogen synthase kinase-3, comprising administering to a mammal, including man in need of such
25 prevention and/or treatment, a therapeutically effective amount of a compound of formula I as defined in any one of claims 1 to 7.

18. A method of prevention and/or treatment of dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia
30 complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica, comprising administering to a mammal, including

man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula I as defined in any one of claims 1 to 7.

19. The method according to claim 18, wherein the prevention and/or treatment is for
5 Alzheimer's Disease.


20. A method of prevention and/or treatment of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head
10 trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss and contraceptive medication, Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula I as defined in any
15 one of claims 1 to 7.

21. The method according to claim 18, wherein the prevention and/or treatment is Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders.

22. A method of prevention and/or treatment of predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular
20 dementia, dementia with Lewy bodies, Frontotemporal dementia and androgenetic alopecia, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula I as defined in any one of claims 1 to 7.

23. A process for the preparation of a compound of formula I according to claim 1,
30 wherein Y, X, Z, P, Q, R, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², A, m and n are defined as in formula I, comprising of de-halogen coupling of a compound of formula IV with an appropriate aryl species;


60



5 to give a compound of formula I.

24. A process for the preparation of a compound of formula I according to claim 1, wherein Y, X, Z, P, Q, R, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², A, m and n are defined as in formula I, comprising reacting of a compound of formula XXII:

10




15

wherein the reaction is being performed by activation of a compound of formula XXII by treatment with a coupling agent or with an acyl halide reagent followed by treatment with the appropriate amine, followed by cleavage of the solid phase moiety by treatment with a suitable acid in a suitable solvent, and where the reaction temperature is between 0 °C and reflux, to give a compound of formula I.

20

25. A compound of formula XIXa



5 wherein

P is phenyl

R¹ and R² are independently selected from hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylheterocycloalkyl, C₁₋₆alkylNR⁶R⁷,

C₀₋₆alkylaryl and C₀₋₆alkylheteroaryl, wherein any C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,

10 C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylheterocycloalkyl, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl may be substituted by one or more A;

R¹ and R² may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A;

15 R³ is independently selected from halogen, nitro, CHO, C₀₋₆alkylCN, OC₁₋₆alkylCN, C₀₋₆alkylOR⁶, OC₁₋₆alkylOR⁶, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C₀₋₆alkylNR⁶R⁷, OC₁₋₆alkylNR⁶R⁷, OC₁₋₆alkylOC₁₋₆alkylNR⁶R⁷, NR⁶OR⁷, C₀₋₆alkylCO₂R⁶, OC₁₋₆alkylCO₂R⁶,

C₀₋₆alkylCONR⁶R⁷, OC₁₋₆alkylCONR⁶R⁷, OC₁₋₆alkylNR⁶(CO)R⁷, C₀₋₆alkylNR⁶(CO)R⁷, O(CO)NR⁶R⁷, NR⁶(CO)OR⁷, NR⁶(CO)NR⁶R⁷, O(CO)OR⁶, O(CO)R⁶, C₀₋₆alkylCOR⁶, OC₁₋₆alkylCOR⁶, NR⁶(CO)(CO)R⁶, NR⁶(CO)(CO)NR⁶R⁷, SR⁶, C₀₋₆alkyl(SO₂)NR⁶R⁷, OC₁₋₆alkylNR⁶(SO₂)R⁷, OC₀₋₆alkyl(SO₂)NR⁶R⁷, C₀₋₆alkyl(SO)NR⁶R⁷,

OC₁₋₆alkyl(SO)NR⁶R⁷, SO₃R⁶, C₀₋₆alkylNR⁶(SO₂)NR⁶R⁷, C₀₋₆alkylNR⁶(SO)R⁷, OC₁₋₆alkylNR⁶(SO)R⁷, OC₀₋₆alkylSO₂R⁶, C₀₋₆alkylSO₂R⁶, C₀₋₆alkylSOR⁶, C₁₋₆alkyl,

25 C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl and C₀₋₆alkylheteroaryl, wherein any C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl and C₀₋₆alkylheteroaryl may be optionally substituted by one or more A;

R⁶ and R⁷ are independently selected from hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl and C₁₋₆alkylNR⁸R⁹;


R^6 and R^7 may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A and wherein a CH_2 group may optionally be replaced by a CO group;

- 5 R^8 and R^9 are independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{0-6} alkyl C_{3-6} cycloalkyl, C_{0-6} alkylaryl and C_{0-6} alkylheteroaryl;

R^8 and R^9 may together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which heterocyclic ring may be optionally substituted by A;

- 10 m is 0, 1, 2, 3 or 4;

R^{15} is a group outlined in Scheme I, wherein R^{16} and R^{17} are hydroxy and B is boron;



A is halogen, oxo ($=O$), nitro, CHO, CN, OR^6 , C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl,

- 15 C_{0-6} alkyl C_{3-6} cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C_{0-6} alkyl NR^6R^7 , OC_{1-6} alkyl NR^6R^7 , CO_2R^8 , $CONR^6R^7$, $NR^6(CO)R^6$, $O(CO)R^6$, COR^6 , SR^6 , $(SO_2)NR^6R^7$, $(SO)NR^6R^7$, SO_3R^6 , SO_2R^6 or SOR^6 ; as a free base or a salt, solvate or solvate of a salt thereof.

- 20 26. A compound according to claim 25, wherein

R^1 and R^2 together forms a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A;

m is 0;

- 25 A is C_{1-6} alkyl; as a free base or a salt, solvate or solvate of a salt thereof.


27. A compound which is

4-(Pyrrolidin-1-ylsulfonyl)phenylboronic acid;

4-[(4-Methylpiperazin-1-yl)sulfonyl]phenylboronic acid;

5 as a free base or a salt, solvate or solvate of a salt thereof.

28. A compound of formula IV



10 (IV)

wherein

Y is CONR^5 , NR^5CO , SO_2NR^5 , NR^5SO_2 , CH_2NR^5 , NR^5CONR^5 , CH_2CO , CO or CH_2O ;

X is CH or N;

Z is N;

15 Q is $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$ or $\text{C}_{2-6}\text{alkynyl}$;

R^4 is independently selected from halogen, nitro, CHO, CN, $\text{OC}_{1-6}\text{alkylCN}$, OR^6 ,

$\text{OC}_{1-6}\text{alkylOR}^6$, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy,

difluoromethoxy, trifluoromethoxy, NR^6R^7 , $\text{OC}_{1-6}\text{alkylNR}^6\text{R}^7$, NR^6OR^7 , CO_2R^6 ,

$\text{OC}_{1-6}\text{alkylCO}_2\text{R}^6$, CONR^6R^7 , $\text{OC}_{1-6}\text{alkylCONR}^6\text{R}^7$, $\text{OC}_{1-6}\text{alkylNR}^6(\text{CO})\text{R}^7$, $\text{NR}^6(\text{CO})\text{R}^7$,

20 $\text{O}(\text{CO})\text{NR}^6\text{R}^7$, $\text{NR}^6(\text{CO})\text{OR}^7$, $\text{NR}^6(\text{CO})\text{NR}^6\text{R}^7$, $\text{O}(\text{CO})\text{OR}^6$, $\text{O}(\text{CO})\text{R}^6$, COR^6 ,

$\text{OC}_{1-6}\text{alkylCOR}^6$, $\text{NR}^6(\text{CO})(\text{CO})\text{R}^6$, $\text{NR}^6(\text{CO})(\text{CO})\text{NR}^6\text{R}^7$, SR^6 , $(\text{SO}_2)\text{NR}^6\text{R}^7$,

$\text{OC}_{1-6}\text{alkylNR}^6(\text{SO}_2)\text{R}^7$, $\text{OC}_{0-6}\text{alkyl}(\text{SO}_2)\text{NR}^6\text{R}^7$, $(\text{SO})\text{NR}^6\text{R}^7$, $\text{OC}_{1-6}\text{alkyl}(\text{SO})\text{NR}^6\text{R}^7$,

SO_3R^6 , $\text{NR}^6(\text{SO}_2)\text{NR}^6\text{R}^7$, $\text{NR}^6(\text{SO})\text{R}^7$, $\text{OC}_{1-6}\text{alkylNR}^6(\text{SO})\text{R}^7$, $\text{OC}_{0-6}\text{alkylSO}_2\text{R}^6$, SO_2R^6 ,

SOR^6 , $\text{C}_{3-6}\text{cycloalkyl}$, phenyl, a 5 or 6 membered heteroaromatic ring containing one or

25 more heteroatoms independently selected from N, O, or S, or a 5 or 6 membered

heterocyclic ring containing one or more heteroatoms independently selected from N, O, or

S which heterocyclic group may be saturated or unsaturated, and said phenyl ring or 5 or 6

membered heteroaromatic ring or 5 or 6 membered heterocyclic ring may optionally be

fused with a 5 or 6 membered saturated, partially saturated or unsaturated ring containing

atoms independently selected from C, N, O or S wherein any C₃₋₆cycloalkyl, phenyl, 5 or 6 membered heteroaromatic ring with one or two heteroatoms selected independently from N, O, or S or a 5 or 6 membered heterocyclic ring containing one or two heteroatoms selected independently from N, O, or S; may be optionally be substituted by one or more

5 A;

R⁵ is hydrogen or C₁₋₆alkyl

R⁶ and R⁷ are independently selected from hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl and C₁₋₆alkylNR⁸R⁹;

10 R⁶ and R⁷ may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A and wherein a CH₂ group may optionally be replaced by a CO group;

R⁸ and R⁹ are independently selected from hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl and C₀₋₆alkylheteroaryl;

15 R⁸ and R⁹ may together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which heterocyclic ring may be optionally substituted by A;

Hal is halogen;

n is 0, 1, 2, 3 or 4;

20 A is halogen, oxo (=O), nitro, CHO, CN, OR⁶, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C₀₋₆alkylNR⁶R⁷, OC₁₋₆alkylNR⁶R⁷, CO₂R⁸, CONR⁶R⁷, NR⁶(CO)R⁶, O(CO)R⁶, COR⁶, SR⁶, (SO₂)NR⁶R⁷, (SO)NR⁶R⁷, SO₃R⁶, SO₂R⁶ or SOR⁶; as a free base or a salt, solvate or solvate of a salt thereof.

25

29. A compound according to claim 28, wherein

Y is CONR⁵;

X is N;

Q is C₁₋₆alkyl;

30 R⁴ is independently selected from CN, OR⁶, a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms independently selected from N, O, or S, or a 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected

from N, O, or S which heterocyclic group may be saturated or unsaturated, wherein any 5 or 6 membered heterocyclic ring containing one or two heteroatoms selected independently from N, O, or S; may be optionally be substituted by A;

R⁵ is hydrogen;

5 R⁶ is, C₁₋₆alkyl;

n is 1;

A is oxo (=O);

as a free base or a salt, solvate or solvate of a salt thereof.

10 30. A compound which is

3-Amino-6-bromo-*N*-(2-morpholin-4-ylethyl)pyrazine-2-carboxamide;

3-Amino-6-bromo-*N*-[2-(1*H*-imidazol-4-yl)ethyl]pyrazine-2-carboxamide;

3-Amino-6-bromo-*N*-[3-(1*H*-imidazol-1-yl)propyl]pyrazine-2-carboxamide;

3-Amino-6-bromo-*N*-(2-thien-2-ylethyl)pyrazine-2-carboxamide;

15 3-Amino-6-bromo-*N*-(thien-2-ylmethyl)pyrazine-2-carboxamide;

3-Amino-6-bromo-*N*-(2-methoxyethyl)pyrazine-2-carboxamide;


3-Amino-6-bromo-*N*-(3-methoxypropyl)pyrazine-2-carboxamide;

3-Amino-6-bromo-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]pyrazine-2-carboxamide;

3-Amino-6-bromo-*N*-(cyanomethyl)pyrazine-2-carboxamide;

20 as a free base or a salt, solvate or solvate of a salt thereof.

31. A compound of formula **XXII**



(XXII)

wherein:

Z is N;

X is CH or N;

P is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms
 5 selected from N, O or S and said phenyl ring or 5 or 6 membered heteroaromatic ring may optionally be fused with a 5 or 6 membered saturated, partially saturated or unsaturated ring containing atoms independently selected from C, N, O or S;

R is CHO, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C₀₋₆alkyl(SO₂)NR¹R²,
 OC₀₋₆alkyl(SO₂)NR¹R², OC₁₋₆alkyl(SO)NR¹R², C₁₋₆alkyl(SO)NR¹R², C₀₋₆alkylNR¹(SO)R²,
 10 OC₁₋₆alkylNR¹(SO)R², C₀₋₆alkylNR¹(SO₂)NR¹R², OC₁₋₆alkylNR¹(SO₂)R²,
 C₀₋₆alkyl(SO₂)C₁₋₆alkylNR¹R², OC₀₋₆alkyl(SO₂)C₁₋₆alkylNR¹R²,
 C₀₋₆alkyl(SO)C₁₋₆alkylNR¹R², OC₁₋₆alkyl(SO)C₁₋₆alkylNR¹R², C₀₋₆alkylSC₁₋₆alkylNR¹R²,
 OC₁₋₆alkylSC₁₋₆alkylNR¹R², OC₁₋₆alkylOC₁₋₆alkyl, C₁₋₆alkylOC₁₋₆alkylNR¹R²,
 OC₁₋₆alkylOC₁₋₆alkylNR¹R², C₀₋₆alkylCONR¹⁰R¹¹, OC₀₋₆alkylCONR¹R²,
 15 OC₁₋₆alkylNR¹R², C₀₋₆alkylNR¹⁰(CO)R¹¹, OC₁₋₆alkylNR¹(CO)R², C₀₋₆alkylNR¹¹(CO)R¹⁰,
 C₀₋₆alkylCOR¹¹, OC₁₋₆alkylCOR¹, C₀₋₆alkylNR¹⁰R¹¹, C₀₋₆alkylO(CO)R¹¹,
 OC₁₋₆alkylO(CO)R¹, C₀₋₆alkylC(NR¹⁰)NR¹⁰R¹¹, C₀₋₆alkylC(NR¹¹)N(R¹⁰)₂,
 OC₀₋₆alkylC(NR¹)NR¹R², C₀₋₆alkylNR¹⁰(CO)OR¹¹, OC₁₋₆alkylNR¹(CO)OR²,
 C₀₋₆alkylNR¹¹(CO)OR¹⁰, OC₁₋₆alkylCN, NR¹OR², C₀₋₆alkyl(CO)OR⁸, OC₁₋₆alkyl(CO)OR¹,
 20 NR¹(CO)NR¹R², NR¹(CO)(CO)R², NR¹(CO)(CO)NR¹R², OR¹² or SO₃R¹;

R¹ and R² are independently selected from hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,
 C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylheterocycloalkyl, C₁₋₆alkylNR⁶R⁷,
 C₀₋₆alkylaryl and C₀₋₆alkylheteroaryl, wherein any C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,
 C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylheterocycloalkyl, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl may
 25 be substituted by one or more A;

R¹ and R² may together form a substituted 5 or 6 membered heterocyclic ring containing
 one or more heteroatoms independently selected from N, O or S, which heterocyclic ring
 may be optionally substituted by A;

R³ is independently selected from halogen, nitro, CHO, C₀₋₆alkylCN, OC₁₋₆alkylCN,
 30 C₀₋₆alkylOR⁶, OC₁₋₆alkylOR⁶, fluoromethyl, difluoromethyl, trifluoromethyl,
 fluoromethoxy, difluoromethoxy, trifluoromethoxy, C₀₋₆alkylNR⁶R⁷, OC₁₋₆alkylNR⁶R⁷,
 OC₁₋₆alkylOC₁₋₆alkylNR⁶R⁷, NR⁶OR⁷, C₀₋₆alkylCO₂R⁶, OC₁₋₆alkylCO₂R⁶,

- $C_{0-6}alkylCONR^6R^7$, $OC_{1-6}alkylCONR^6R^7$, $OC_{1-6}alkylNR^6(CO)R^7$, $C_{0-6}alkylNR^6(CO)R^7$,
 $O(CO)NR^6R^7$, $NR^6(CO)OR^7$, $NR^6(CO)NR^6R^7$, $O(CO)OR^6$, $O(CO)R^6$, $C_{0-6}alkylCOR^6$,
 $OC_{1-6}alkylCOR^6$, $NR^6(CO)(CO)R^6$, $NR^6(CO)(CO)NR^6R^7$, SR^6 , $C_{0-6}alkyl(SO_2)NR^6R^7$,
 $OC_{1-6}alkylNR^6(SO_2)R^7$, $OC_{0-6}alkyl(SO_2)NR^6R^7$, $C_{0-6}alkyl(SO)NR^6R^7$,
5 $OC_{1-6}alkyl(SO)NR^6R^7$, SO_3R^6 , $C_{0-6}alkylNR^6(SO_2)NR^6R^7$, $C_{0-6}alkylNR^6(SO)R^7$,
 $OC_{1-6}alkylNR^6(SO)R^7$, $OC_{0-6}alkylSO_2R^6$, $C_{0-6}alkylSO_2R^6$, $C_{0-6}alkylSOR^6$, $C_{1-6}alkyl$,
 $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{0-6}alkylC_{3-6}cycloalkyl$, $C_{0-6}alkylaryl$ and $C_{0-6}alkylheteroaryl$,
wherein any $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{0-6}alkylC_{3-6}cycloalkyl$, $C_{0-6}alkylaryl$ and
 $C_{0-6}alkylheteroaryl$ may be optionally substituted by one or more A;
10 R^6 and R^7 are independently selected from hydrogen, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$,
 $C_{0-6}alkylC_{3-6}cycloalkyl$, $C_{0-6}alkylaryl$, $C_{0-6}alkylheteroaryl$ and $C_{1-6}alkylNR^8R^9$;
 R^6 and R^7 may together form a substituted 5 or 6 membered heterocyclic ring containing
one or more heteroatoms independently selected from N, O or S, which heterocyclic ring
may be optionally substituted by A and wherein a CH_2 group may optionally be replaced
15 by a CO group;
 R^8 and R^9 are independently selected from hydrogen, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$,
 $C_{0-6}alkylC_{3-6}cycloalkyl$, $C_{0-6}alkylaryl$ and $C_{0-6}alkylheteroaryl$;
 R^8 and R^9 may together form a 5 or 6 membered heterocyclic ring containing one or more
heteroatoms selected from N, O or S, which heterocyclic ring may be optionally
20 substituted by A;
 R^{10} is hydrogen, $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $C_{0-6}alkylC_{3-6}cycloalkyl$,
 $C_{0-6}alkylaryl$, $C_{0-6}alkylheteroaryl$ or $C_{1-6}alkylNR^8R^9$;
 R^{11} is $C_{1-6}alkylNR^8R^9$;
 R^{10} and R^{11} may together form a 5 or 6 membered heterocyclic ring containing one or more
25 heteroatoms selected from N, O or S, which heterocyclic ring may be optionally
substituted by A;
A is halogen, oxo (=O), nitro, CHO, CN, OR^6 , $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$,
 $C_{0-6}alkylC_{3-6}cycloalkyl$, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy,
difluoromethoxy, trifluoromethoxy, $C_{0-6}alkylNR^6R^7$, $OC_{1-6}alkylNR^6R^7$, CO_2R^8 , $CONR^6R^7$,
30 $NR^6(CO)R^6$, $O(CO)R^6$, COR^6 , SR^6 , $(SO_2)NR^6R^7$, $(SO)NR^6R^7$, SO_3R^6 , SO_2R^6 or SOR^6 ;
m is 0, 1, 2, 3 or 4;
as a free base or a salt, solvate or solvate of a salt thereof.

32. A compound according to claim 31, wherein:

X is N;

P is phenyl;

5 R is C₀₋₆alkyl(SO₂)NR¹R²;

R¹ and R² may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S;

m is 0;

as a free base or a salt, solvate or solvate of a salt thereof.

10

33. A compound which is

Methyl 3-{[2,6-dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate polystyrene;

3-{[2,6-Dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-

15 ylsulfonyl)phenyl]pyrazine-2-carboxylic acid polystyrene;

as a free base or a salt, solvate or solvate of a salt thereof.

34. The use of the intermediates according to any one of claims to 25 to 33 for the preparation of a compound of formula I as defined in any one of claims 1 to 7.

20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2003/001957

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 403/12, C07D 403/14, C07D 401/12, C07D 401/14, C07D 413/14,
A61K 31/497, A61K 31/496, A61K 31/5377, A61P 25/00, 5/10, 5/48, 15/18, 17/14
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CHEM.ABS.DATA, WPI DATA, EPO-INTERNAL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 03093297 A2 (EXELIXIS, INC.), 13 November 2003 (13.11.2003) --	1,8-10
X	WO 0168612 A2 (COCENSYS, INC.), 20 Sept 2001 (20.09.2001) --	1-24
X	US 2001031772 A1 (KARL SCHOENAFINGER ET AL), 18 October 2001 (18.10.2001) --	1-24
A	WO 02092585 A1 (BIOVITRUM AB), 21 November 2002 (21.11.2002) --	1-24

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

19 April 2004

Date of mailing of the international search report

20-04-2004

Name and mailing address of the ISA/

Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

EVA JOHANSSON/BS
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 2003/001957

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 0160806 A2 (NEUROGEN CORPORATION), 23 August 2001 (23.08.2001) --	1-24
A	US 6255307 B1 (BRIAN COX ET AL), 3 July 2001 (03.07.2001) -- -----	1-24

INTERNATIONAL SEARCH REPORT

Information on patent family members

31/03/2004

International application No.

PCT/SE 2003/001957

WO	03093297	A2	13/11/2003	NONE		
WO	0168612	A2	20/09/2001	AP	200202629 D	00/00/0000
				AU	4562001 A	24/09/2001
				CA	2400945 A	20/09/2001
				CN	1422254 T	04/06/2003
				EP	1265866 A	18/12/2002
				HU	0300466 A	28/07/2003
				IL	151417 D	00/00/0000
				JP	2003527376 T	16/09/2003
				NO	20024308 A	08/11/2002
				US	2002040025 A	04/04/2002
US	2001031772	A1	18/10/2001	AU	3378701 A	17/09/2001
				BR	0108974 A	03/06/2003
				CA	2401953 A	13/09/2001
				CN	1416424 T	07/05/2003
				DE	10010968 A	13/09/2001
				EE	200200498 A	16/02/2004
				EP	1263745 A	11/12/2002
				HU	0302772 A	28/11/2003
				IL	151518 D	00/00/0000
				JP	2003525931 T	02/09/2003
				NO	20024201 A	03/09/2002
				SK	12752002 A	01/04/2003
				US	6369088 B	09/04/2002
				WO	0166531 A	13/09/2001
				ZA	200207146 A	15/05/2003
				DE	10102265 C	08/08/2002
WO	02092585	A1	21/11/2002	AU	7287501 A	05/02/2002
				CA	2443724 A	21/11/2002
				NO	20034996 D	00/00/0000
				SE	0101659 D	00/00/0000
				US	2003149019 A	07/08/2003
				US	2003149020 A	07/08/2003
				AU	8273501 A	18/02/2002
				GB	0301788 D	00/00/0000
				GB	2382279 A	21/05/2003
				SE	0101660 D	00/00/0000
				AU	8816101 A	26/03/2002
				EP	1317232 A	11/06/2003
				SE	0101958 D	00/00/0000

INTERNATIONAL SEARCH REPORT

Information on patent family members

31/03/2004

International application No.

PCT/SE 2003/001957

WO	0160806	A2	23/08/2001	AU	3849401	A	27/08/2001
				BG	106968	A	30/04/2003
				BR	0108363	A	10/02/2004
				CA	2398937	A	23/08/2001
				CN	1400970	T	05/03/2003
				CZ	20022739	A	12/02/2003
				EE	200200453	A	15/12/2003
				EP	1255740	A	13/11/2002
				HU	0301573	A	29/12/2003
				IL	151020	D	00/00/0000
				JP	2004500383	T	08/01/2004
				NO	20023869	A	11/09/2002
				SK	11542002	A	04/03/2003
				US	2003018035	A	23/01/2003
				ZA	200206103	A	20/08/2003
<hr/>							
US	6255307	B1	03/07/2001	AP	9901632	D	00/00/0000
				AT	251143	T	15/10/2003
				AU	732915	B	03/05/2001
				AU	6823798	A	18/09/1998
				BG	103723	A	31/05/2001
				BR	9807814	A	22/02/2000
				CA	2282585	A	03/09/1998
				DE	69818643	D	00/00/0000
				DK	966448	T	02/02/2004
				EA	2102	B	00/00/0000
				EE	9900376	A	17/04/2000
				EP	0966448	A,B	29/12/1999
				SE	0966448	T3	
				HU	0001802	A	28/05/2001
				IL	131293	A	31/07/2003
				JP	3369189	B	20/01/2003
				JP	2000511203	T	29/08/2000
				NO	313383	B	23/09/2002
				NO	994213	A	29/10/1999
				NZ	337121	A	30/03/2001
				SK	117399	A	12/06/2000
				US	6599905	B	29/07/2003
				US	2002169172	A	14/11/2002
				CN	1105111	B	09/04/2003
				CN	1253551	T	17/05/2000
				GB	9704275	D	00/00/0000
				HR	980107	A	31/12/1998
				ID	22850	A	00/00/0000
				PL	335441	A	25/04/2000
				TR	9902082	T	00/00/0000
				TW	513416	B	00/00/0000
				WO	9838174	A	03/09/1998
				ZA	9801624	A	26/08/1999
				GB	9708183	D	00/00/0000
				JP	2002308773	A	23/10/2002

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2003/001957**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **17-22**
because they relate to subject matter not required to be searched by this Authority, namely:
see extra sheet
2. ☒ Claims Nos.: **9, 11, 17**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
see extra sheet
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see extra sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-24

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2003/001957

Box II.1

Claims 17-22 relate to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practiced on the human or animal body (Rule 39.1(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds or compositions.

Box II.2

The expression "conditions associated with glycogen synthase kinase-3" in claims 9, 11 and 17 is not clear and concise and does not comply with PCT Articles 5 and 6 as it defines the conditions by the mechanism behind the conditions and does not mention the specific conditions. It is therefore not clear which conditions are comprised by these claims. The search has been performed on the general expression in some parts but has mainly been focused on the conditions named in claims 12, 14 and 16.

Box III

According to PCT Article 34 (3) (a-c) and Rule 13.2, an application shall relate to one invention only or to a group of inventions linked by one or more of the same or corresponding "special technical features", i.e. features that define a contribution which each of the inventions makes over the prior art. In order to consider that end products and intermediates represents one invention it is necessary that the essential structural elements of the end product also can be found in the intermediate. Claims 25-34 of the present application relate to a number of intermediates and their use. These compounds are not considered to have enough structural similarity with the end products to fulfil the demands of unity. The compounds defined of the application have been divided into four inventions according to the following:

- 1) Compounds according to formula I. Pharmaceutical formulations, use and methods involving these compounds and processes for the preparation of the compounds. Claims 1-24.
- 2) Compounds according to formula XIXa and their use. Claims 25-27 and 34 partially.

--/...

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE2003/001957

3) Compounds according to formula IV and their use. Claims 28-30 and 34 partially.

4) Compounds according to formula XXII and their use. Claims 31-33 and 34 partially.

Only invention I (claims 1-24) has been searched.